Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Spontaneous
Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility.
Acquired Immunodeficiency Syndrome
GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity.
Adenocarcinoma
68Ga-Labeled Prostate-Specific Membrane Antigen Uptake in Pheochromocytoma: An Incidental Finding in PET/CT Scan.
Adenocarcinoma
A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients.
Adenocarcinoma
Cloning and characterization of the prostate-specific membrane antigen promoter.
Adenocarcinoma
Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer.
Adenocarcinoma
Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen.
Adenocarcinoma
Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Adenocarcinoma
Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Adenocarcinoma
Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: Implications for novel intraoperative PSMA-based fluorescent imaging techniques.
Adenocarcinoma
GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond.
Adenocarcinoma
Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy.
Adenocarcinoma
Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis.
Adenocarcinoma
In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.
Adenocarcinoma
Incidental Meningioma Mimicking Metastasis of Prostate Adenocarcinoma in 68Ga-Labeled PSMA Ligand PET/CT.
Adenocarcinoma
Intense fluoro-2-deoxyglucose uptake in high-grade prostatic adenocarcinoma with negligible prostate-specific membrane antigen expression.
Adenocarcinoma
Loss of PSMA Expression in Non-neuroendocrine Dedifferentiated Acinar Prostate Cancer.
Adenocarcinoma
Making the Case for Prostate-Specific Membrane Antigen-Targeted Positron Emission Tomography/Computed Tomography in Suspected Prostate Cancer.
Adenocarcinoma
Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase).
Adenocarcinoma
Monoclonal antibodies and prostate-specific membrane antigen.
Adenocarcinoma
Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice.
Adenocarcinoma
Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
Neuroendocrine differentiation of prostate cancer leads to PSMA suppression.
Adenocarcinoma
New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen.
Adenocarcinoma
Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions.
Adenocarcinoma
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Adenocarcinoma
Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.
Adenocarcinoma
Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma.
Adenocarcinoma
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
Adenocarcinoma
Prostate-specific membrane antigen.
Adenocarcinoma
PSMA ligand conjugated PCL-PEG polymeric micelles targeted to prostate cancer cells.
Adenocarcinoma
Radium and other alpha emitters in prostate cancer.
Adenocarcinoma
Recombinant Adenovirus Mediated Prostate-Specific Enzyme Pro-Drug Gene Therapy Regulated by Prostate-Specific Membrane Antigen (PSMA) Enhancer/Promoter.
Adenocarcinoma
Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma.
Adenocarcinoma
Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.
Adenocarcinoma
Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.
Adenocarcinoma
The use of nested RT-PCR of prostate-specific membrane antigen in blood cells: implications for the detection of haematogenous neoplastic cells in patients with prostate adenocarcinoma.
Adenocarcinoma
Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer.
Adenomatous Polyps
Genetic Variation in Glutamate Carboxypeptidase II and Interaction with Dietary Natural Vitamin C May Predict Risk for Adenomatous Polyp Occurrence.
Adrenocortical Carcinoma
Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma.
Adrenocortical Carcinoma
Prostate-Specific Membrane Antigen Expression in Adrenocortical Carcinoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Adrenocortical Carcinoma
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma.
Alzheimer Disease
Expression of glutamate carboxypeptidase II in human brain.
Alzheimer Disease
Glutamate carboxypeptidase II does not process amyloid-? peptide.
Alzheimer Disease
Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.
Alzheimer Disease
Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain.
Alzheimer Disease
N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
Alzheimer Disease
N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases.
Alzheimer Disease
NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.
Amyotrophic Lateral Sclerosis
Expression of glutamate carboxypeptidase II in human brain.
Amyotrophic Lateral Sclerosis
Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models.
Amyotrophic Lateral Sclerosis
N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases.
Amyotrophic Lateral Sclerosis
NAALADase inhibition protects motor neurons against chronic glutamate toxicity.
Amyotrophic Lateral Sclerosis
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Anencephaly
Role of parental folate pathway single nucleotide polymorphisms in altering the susceptibility to neural tube defects in South India.
Angiofibroma
Advantage of 68Ga-PSMA PET/CT on Postradiotherapy Response Assessment of Juvenile Nasal Angiofibroma.
Angiofibroma
Comparison of 68Ga-PSMA PET/CT and Contrast-Enhanced MRI on Residual Disease Assessment of Juvenile Nasal Angiofibroma.
Angiofibroma
Fusion 68Ga-Prostate-Specific Membrane Antigen PET/MRI on Postoperative Surveillance of Juvenile Nasal Angiofibroma.
Angiofibroma
Physiological PSMA Uptake in the Tubarial Salivary Glands and Its Implications in the PARIS Protocol-A First Study of Its Kind!
Angiofibroma
Pterygoid Base Pneumatization Simulating Residual Disease-A Pitfall of Structural Imaging in Juvenile Nasal Angiofibroma.
Angiofibroma
Validation of Postoperative Angiofibroma Radionuclide Imaging Study (PARIS) Protocol Using PSMA PET/CT-A Proof of Concept Study.
Angiolipoma
Prostate-specific membrane antigen expressing angiolipoma.
aspartoacylase deficiency
Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain.
Ataxia Telangiectasia
Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer.
Blindness
RasGRF1 disruption causes retinal photoreception defects and associated transcriptomic alterations.
Bone Neoplasms
Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain: [La ketamine et un inhibiteur N-acetylaspartylglutamate peptidase exercent une analgesie sur la douleur du cancer des os].
Brain Diseases
Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes.
Brain Injuries
Electroencephalogram analysis and neuroprotective profile of the N-acetylated-alpha-linked acidic dipeptidase inhibitor, GPI5232, in normal and brain-injured rats.
Brain Injuries
Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury.
Brain Injuries
Neuroprotective effects of N-acetylaspartylglutamate in a neonatal rat model of hypoxia-ischemia.
Brain Injuries
Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.
Brain Injuries
Suppression of Glutamate Carboxypeptidase II Ameliorates Neuronal Apoptosis from Ischemic Brain Injury.
Brain Injuries, Traumatic
Glutamate carboxypeptidase II gene knockout attenuates oxidative stress and cortical apoptosis after traumatic brain injury.
Brain Injuries, Traumatic
Metabolite differences between glutamate carboxypeptidase II gene knockout mice and their wild-type littermates after traumatic brain injury: a 7-tesla 1H-MRS study.
Brain Injuries, Traumatic
Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury.
Brain Ischemia
Blockade of NAALADase: a novel neuroprotective strategy based on limiting glutamate and elevating NAAG.
Brain Neoplasms
Novel solid-phase strategy for the synthesis of ligand-targeted fluorescent-labelled chelating peptide conjugates as a theranostic tool for cancer.
Brain Neoplasms
Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with
Brain Neoplasms
Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.
Brain Neoplasms
Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain.
Brain Neoplasms
The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?
Breast Neoplasms
68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.
Breast Neoplasms
68Ga-PSMA PET/CT in the evaluation of locally advanced and metastatic breast cancer, a single center experience.
Breast Neoplasms
Association of glutamate carboxypeptidase II (GCPII) haplotypes with breast and prostate cancer risk.
Breast Neoplasms
Bone-Targeted Drug Delivery Systems and Strategies for Treatment of Bone Metastasis.
Breast Neoplasms
Boranophosphate siRNA-aptamer chimeras for tumor-specific downregulation of cancer receptors and modulators.
Breast Neoplasms
Clinical utility of genetic variants of glutamate carboxypeptidase II in predicting breast cancer and prostate cancer risk.
Breast Neoplasms
Combined impact of polymorphism of folate metabolism genes; glutamate carboxypeptidase, methylene tetrahydrofolate reductase and methionine synthase reductase on breast cancer susceptibility in kashmiri women.
Breast Neoplasms
EV-Ident: Identifying Tumor-Specific Extracellular Vesicles by Size Fractionation and Single-Vesicle Analysis.
Breast Neoplasms
Long Half-life (89)Zr Labeled Radiotracers Can Guide In Suite Percutaneous Molecular Imaging PET/CT-guided Biopsies Without Reinjection of Radiotracer.
Breast Neoplasms
Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines.
Breast Neoplasms
Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.
Breast Neoplasms
Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases.
Breast Neoplasms
Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.
Breast Neoplasms
Prostate-specific membrane antigen in breast carcinoma.
Canavan Disease
Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain.
Canavan Disease
RasGRF1 disruption causes retinal photoreception defects and associated transcriptomic alterations.
Carcinogenesis
Association of glutamate carboxypeptidase II (GCPII) haplotypes with breast and prostate cancer risk.
Carcinogenesis
Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
Carcinogenesis
Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain.
Carcinogenesis
Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis.
Carcinoma
18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
Carcinoma
18F-PSMA 1007 in Suspected Renal Cell Carcinoma.
Carcinoma
68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.
Carcinoma
68Ga-PSMA Expression in Pseudoangiomatous Stromal Hyperplasia of the Breast.
Carcinoma
A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine.
Carcinoma
A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
Carcinoma
A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Carcinoma
A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
Carcinoma
A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR.
Carcinoma
Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy.
Carcinoma
Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine.
Carcinoma
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer.
Carcinoma
Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients.
Carcinoma
Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Carcinoma
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing.
Carcinoma
Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells.
Carcinoma
Cerebellar Metastases From Prostate Cancer on 68Ga-PSMA PET/CT.
Carcinoma
Comparison of bone scintigraphy and Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography in the detection of bone metastases of prostate carcinoma.
Carcinoma
Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Carcinoma
Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer.
Carcinoma
Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
Carcinoma
Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Carcinoma
Decision-support for treatment with 177Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET/CT and clinical parameters.
Carcinoma
Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA).
Carcinoma
Detection and localization of carcinoma within the prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed at prostate specific membrane antigen (PSMA)-Proof of concept and initial imaging results.
Carcinoma
Diagnostic potential of PET/CT using a (68)Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.
Carcinoma
Discrepancy between Multiparametric Magnetic Resonance Imaging and 68Ga Prostate-Specific Membrane Antigen Positron Emission Tomography: A Simultaneous Acquired Positron Emission Tomography-Magnetic Resonance Imaging Case.
Carcinoma
Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis.
Carcinoma
Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
Carcinoma
Expression of prostate-specific membrane antigen in normal and malignant human tissues.
Carcinoma
Expression of prostate-specific membrane antigen in renal cortical tumors.
Carcinoma
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value?
Carcinoma
Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma.
Carcinoma
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Carcinoma
Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer.
Carcinoma
Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis.
Carcinoma
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.
Carcinoma
Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line.
Carcinoma
Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging.
Carcinoma
In Vivo Visualization of Prostate-Specific Membrane Antigen in Adenoid Cystic Carcinoma of the Salivary Gland.
Carcinoma
In-House Preparation and Quality Control of Ac-225 Prostate-Specific Membrane Antigen-617 for the Targeted Alpha Therapy of Castration-Resistant Prostate Carcinoma.
Carcinoma
Incidental Detection of Hepatocellular Carcinoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT.
Carcinoma
Incidental Detection of Type B2 Thymoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT Imaging.
Carcinoma
Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT.
Carcinoma
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.
Carcinoma
Intense fluoro-2-deoxyglucose uptake in high-grade prostatic adenocarcinoma with negligible prostate-specific membrane antigen expression.
Carcinoma
Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity.
Carcinoma
Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11.
Carcinoma
Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence.
Carcinoma
Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line.
Carcinoma
Lymphangitic Carcinomatosis From Prostate Cancer Identified With Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography Imaging.
Carcinoma
Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy.
Carcinoma
Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.
Carcinoma
Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma.
Carcinoma
Molar Activity of Ga-68 Labeled PSMA Inhibitor Conjugates Determines PET Imaging Results.
Carcinoma
Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy.
Carcinoma
Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.
Carcinoma
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.
Carcinoma
Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII.
Carcinoma
Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.
Carcinoma
Optimization of Labeling PSMA(HBED) with Ethanol-Postprocessed (68)Ga and Its Quality Control Systems.
Carcinoma
Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.
Carcinoma
Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review.
Carcinoma
Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents.
Carcinoma
PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
Carcinoma
PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY.
Carcinoma
Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis.
Carcinoma
Prostate specific membrane antigen (PSMA) in urothelial cell carcinoma (UCC) is associated with tumor grading and staging.
Carcinoma
Prostate specific membrane antigen- a target for imaging and therapy with radionuclides.
Carcinoma
Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck.
Carcinoma
Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy.
Carcinoma
Prostate-specific membrane antigen directed selective thrombotic infarction of tumors.
Carcinoma
Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain.
Carcinoma
Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.
Carcinoma
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Carcinoma
Prostate-specific membrane antigen: evidence for the existence of a second related human gene.
Carcinoma
PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma.
Carcinoma
PSMA expression on neovasculature of solid tumors.
Carcinoma
PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model.
Carcinoma
PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings.
Carcinoma
PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.
Carcinoma
Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid.
Carcinoma
Re; Seniaray N, Verma R, Khanna S, Belho E, Pruthi A, Mahajan H. Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence. Indian J Urol 2020;36:191-9.
Carcinoma
Real-world Israeli single institution experience with PET-PSMA for staging of patients with clinically staged localized prostate carcinoma.
Carcinoma
Rectal Carcinoma on 68Ga-PSMA PET/CT.
Carcinoma
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Carcinoma
Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function.
Carcinoma
Serous Cystadenoma of the Pancreas Showing Uptake on 68Ga PSMA PET/CT.
Carcinoma
Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Carcinoma
Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Carcinoma
Subacute Cortical Infarct Showing Uptake on 68Ga-PSMA PET/CT.
Carcinoma
Targeted Radionuclide Therapy: A Historical and Personal Review.
Carcinoma
The application of prostate specific membrane antigen in CART?cell therapy for treatment of prostate carcinoma (Review).
Carcinoma
The cloning and characterization of a second brain enzyme with NAAG peptidase activity.
Carcinoma
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy.
Carcinoma
The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
Carcinoma
The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
Carcinoma
The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma.
Carcinoma
The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma.
Carcinoma
Triple synchronous tumours of the urinary system with different histologies: a case report.
Carcinoma
Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma - Is PSMA-PET-CT a helpful tool in radiation oncology?
Carcinoma
Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications.
Carcinoma
Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease.
Carcinoma
Utility of (68) Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma.
Carcinoma
What's behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns.
Carcinoma
Widespread Metastatic Prostate Carcinoma Shown by 68Ga-PSMA PET/CT.
Carcinoma
[Correlation study of expression levels of prostate-specific membrane antigen and prostate-specific antigen with Gleason score of prostate carcinoma]
Carcinoma, Adenoid Cystic
In Vivo Visualization of Prostate-Specific Membrane Antigen in Adenoid Cystic Carcinoma of the Salivary Gland.
Carcinoma, Adenoid Cystic
Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck.
Carcinoma, Adenoid Cystic
Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid.
Carcinoma, Adenoid Cystic
Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma - Is PSMA-PET-CT a helpful tool in radiation oncology?
Carcinoma, Hepatocellular
A Case of Well-differentiated Hepatocellular Carcinoma Identified on Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
Carcinoma, Hepatocellular
Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using 68Ga-PSMA PET/CT.
Carcinoma, Hepatocellular
Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Incidental Detection of Hepatocellular Carcinoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT.
Carcinoma, Hepatocellular
Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Carcinoma, Hepatocellular
Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging.
Carcinoma, Hepatocellular
Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
Carcinoma, Hepatocellular
[68 Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma.
Carcinoma, Merkel Cell
Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma.
Carcinoma, Non-Small-Cell Lung
Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.
Carcinoma, Renal Cell
18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
Carcinoma, Renal Cell
18F-PSMA 1007 in Suspected Renal Cell Carcinoma.
Carcinoma, Renal Cell
68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
Carcinoma, Renal Cell
68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.
Carcinoma, Renal Cell
A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
Carcinoma, Renal Cell
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Carcinoma, Renal Cell
Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
Carcinoma, Renal Cell
Diagnostic potential of PET/CT using a (68)Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.
Carcinoma, Renal Cell
Expression of prostate-specific membrane antigen in renal cortical tumors.
Carcinoma, Renal Cell
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Carcinoma, Renal Cell
Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT.
Carcinoma, Renal Cell
Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.
Carcinoma, Renal Cell
Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis.
Carcinoma, Renal Cell
PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings.
Carcinoma, Renal Cell
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Carcinoma, Renal Cell
The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
Carcinoma, Renal Cell
Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease.
Carcinoma, Renal Cell
Utility of (68) Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma.
Carcinoma, Small Cell
Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Carcinoma, Squamous Cell
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.
Carcinoma, Transitional Cell
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value?
Cardiovascular Diseases
Influence of a glutamate carboxypeptidase II (GCPII) polymorphism (1561C-->T) on plasma homocysteine, folate and vitamin B(12) levels and its relationship to cardiovascular disease risk.
Central Nervous System Diseases
Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay.
Cholangiocarcinoma
Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Colitis
FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.
Colitis, Ulcerative
Inflammatory bowel disease and prostate cancer risk: A systematic review.
Colorectal Neoplasms
In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer--changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile.
Colorectal Neoplasms
Prostate-specific membrane antigen (PSMA) immunoexpression in the neovasculature of colorectal carcinoma in Egyptian patients.
Colorectal Neoplasms
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers.
Colorectal Neoplasms
The reduced folate carrier (RFC1) 80G > A and folate hydrolase 1 (FOLH1) 1561C > T polymorphisms and the risk of colorectal cancer: a nested case-referent study.
Colorectal Neoplasms
The reduced folate carrier (RFC1) 80G>A and folate hydrolase 1 (FOLH1) 1561C>T polymorphisms and the risk of colorectal cancer: a nested case-referent study.
Confusion
Clearing up the confusion over the glutamate carboxypeptidase II gene.
Coronary Artery Disease
Oxidative Stress is Associated with Genetic Polymorphisms in One-Carbon Metabolism in Coronary Artery Disease.
Crohn Disease
Inflammatory bowel disease and prostate cancer risk: A systematic review.
Dementia
Topics of nuclear medicine research in Europe.
Diabetes Mellitus, Type 2
Androgen receptor overexpression in prostate cancer in type 2 diabetes.
Diabetic Neuropathies
GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats.
Diabetic Neuropathies
Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3.
Diabetic Neuropathies
The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy.
Diverticulum
Intense 68Ga-PSMA Uptake in Diverticulum of the Sigmoid Colon.
Encephalomyelitis
Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis.
Encephalomyelitis
Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.
Epilepsy
Expression of glutamate carboxypeptidase II in human brain.
Epilepsy
N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases.
Fasciitis
Low 68Ga-PSMA PET/CT Uptake in Chronic Intramuscular Nodular Fasciitis.
Fibroma
Prostate-Specific Membrane Antigen in Low-Grade Fibromatosis.
Folic Acid Deficiency
Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: Implications for neurodevelopmental disorders.
Gastrointestinal Stromal Tumors
Incidental finding of ileal gastrointestinal stromal tumour during prostate cancer staging with prostate-specific membrane antigen scan.
Glioblastoma
68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.
Glioblastoma
Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients.
Glioblastoma
In vivo visualization of prostate-specific membrane antigen in glioblastoma.
Glioblastoma
Prostate-Specific Membrane Antigen (PSMA) Promotes Angiogenesis of Glioblastoma Through Interacting With ITGB4 and Regulating NF-?B Signaling Pathway.
Glioblastoma
Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.
Glioblastoma
Prostate-Specific Membrane Antigen Expression in Neovasculature of Glioblastoma Multiforme.
Glioblastoma
PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging.
Glioblastoma
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Glioblastoma
Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas.
Glioma
Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Glioma
Expression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and its Correlation with Tumor Grade.
Glioma
Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.
Glioma
Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas.
Glioma
Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas.
Gliosarcoma
The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?
Hearing Loss
RasGRF1 disruption causes retinal photoreception defects and associated transcriptomic alterations.
Hemangioma
Does Prostate-Specific Membrane Antigen Avidity of Vertebral Hemangioma Change?
Hemangioma
Prostate-Specific Membrane Antigen PET/CT Findings for Hepatic Hemangioma.
Hemangiosarcoma
Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.
Hemangiosarcoma
Prostate-Specific Membrane Antigen Expression in Metastatic Angiosarcoma Detected on 18F-PMSA PET/CT: A New Potential Prognostic Marker.
Hemangiosarcoma
Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.
Huntington Disease
Expression of glutamate carboxypeptidase II in human brain.
Hydronephrosis
Renal Pelvis Metastasis From Prostatic Adenocarcinoma Missed by PSMA PET: A Case Report.
Hyperalgesia
Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain.
Hyperalgesia
GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats.
Hyperalgesia
Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat.
Hyperemia
2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in brain of anesthetized mice: evidence of a link between neuron NAAG release and hyperemia.
Hyperhomocysteinemia
Genetic and environmental influences on total plasma homocysteine and coronary artery disease (CAD) risk among South Indians.
Hyperhomocysteinemia
Glutamate carboxypeptidase II (GCPII) genetic variants as determinants of hyperhomocysteinemia: implications in stroke susceptibility.
Hyperhomocysteinemia
Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia.
Hyperkalemia
Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis.
Hypertension
Genetic and environmental influences on total plasma homocysteine and coronary artery disease (CAD) risk among South Indians.
Hypertension
Machine learning algorithm-based risk prediction model of coronary artery disease.
Infarction, Middle Cerebral Artery
Blockade of NAALADase: a novel neuroprotective strategy based on limiting glutamate and elevating NAAG.
Infarction, Middle Cerebral Artery
Electroencephalogram analysis and neuroprotective profile of the N-acetylated-alpha-linked acidic dipeptidase inhibitor, GPI5232, in normal and brain-injured rats.
Infarction, Middle Cerebral Artery
Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation.
Infarction, Middle Cerebral Artery
Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.
Infections
ALTERED MERISTEM PROGRAM1 has conflicting effects on the tolerance to heat shock and symptom development after Pseudomonas syringae infection.
Infections
Multi-component Polymeric System for Tumour Cell-Specific Gene Delivery Using a Universal Bungarotoxin Linker.
Infections
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Inflammatory Bowel Diseases
Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs.
Inflammatory Bowel Diseases
FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.
Inflammatory Bowel Diseases
Inflammatory bowel disease and prostate cancer risk: A systematic review.
Inflammatory Bowel Diseases
Jejunal brush-border folate hydrolase. A novel enzyme.
Inflammatory Bowel Diseases
N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
Influenza, Human
A Phase I Clinical Trial of CD1c (BDCA-1)+ Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer.
Ischemic Stroke
Early-onset ischaemic stroke: analysis of 58 polymorphisms in 17 genes involved in methionine metabolism.
Keloid
Prostate-specific membrane antigen expression in regeneration and repair.
Kidney Neoplasms
Blood-based RT-PCR assays of MN/CA9 or PSMA: clinical application in renal cancer patients.
Kidney Neoplasms
Detection of prostate-specific membrane antigen expressing cells in blood obtained from renal cancer patients: a potential biomarker of vascular invasion.
Kidney Neoplasms
Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.
Kidney Neoplasms
The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
Leukemia
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Lipoma
Incidental Finding of Hibernoma in Prostate-Specific Membrane Antigen PET/CT.
Liposarcoma
Incidental Detection of Tracer Avidity in Liposarcoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT.
Liver Cirrhosis
Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Liver Neoplasms
Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Liver Neoplasms
Synthesis and Biochemical Evaluation of Samarium-153 Oxide Nanoparticles Functionalized with iPSMA-Bombesin Heterodimeric Peptide.
Lung Neoplasms
68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer.
Lung Neoplasms
Comprehensive evaluation of the response of genes to the administration of the antitumor drug S-1 using a low density array.
Lung Neoplasms
Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.
Lung Neoplasms
Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer.
Lung Neoplasms
Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Lung Neoplasms
Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance.
Lung Neoplasms
Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.
Lymphatic Metastasis
68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
Lymphatic Metastasis
68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
Lymphatic Metastasis
68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy.
Lymphatic Metastasis
A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients.
Lymphatic Metastasis
Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer.
Lymphatic Metastasis
Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review.
Lymphatic Metastasis
Diagnostic Performance of ??Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis.
Lymphatic Metastasis
Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
Lymphatic Metastasis
Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer.
Lymphatic Metastasis
Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer.
Lymphatic Metastasis
Pancreatic Ductal Adenocarcinoma With High Radiotracer Uptake in 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Lymphatic Metastasis
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
Lymphatic Metastasis
Prostate-Specific Membrane Antigen PET for Assessment of Primary and Recurrent Prostate Cancer with Histopathology as Reference Standard: A Systematic Review and Meta-Analysis.
Lymphatic Metastasis
Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
Lymphatic Metastasis
Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
Lymphatic Metastasis
Salvage surgery for nodal recurrent prostate cancer.
Lymphatic Metastasis
Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Lymphatic Metastasis
The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
Lymphatic Metastasis
Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia.
Lymphatic Metastasis
Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Lymphedema
Prostate-Specific Membrane Antigen Accumulation in Lower Extremity Lymphedema.
Lymphoma
Relevance of radiobiological concepts in radionuclide therapy of cancer.
Lymphoma, B-Cell
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Lymphoma, Mantle-Cell
Relevance of radiobiological concepts in radionuclide therapy of cancer.
Lymphoma, Non-Hodgkin
Prostate-Specific Membrane Antigen Uptake in Small Cleaved B-Cell Follicular Non-Hodgkin Lymphoma.
Lymphoma, Non-Hodgkin
Relevance of radiobiological concepts in radionuclide therapy of cancer.
Lymphoma, Non-Hodgkin
Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.
Malaria
Possible selection of host folate pathway gene polymorphisms in patients with malaria from a malaria endemic region in North East India.
Measles
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Meckel Diverticulum
Detection of a Meckel's diverticulum on PSMA PET/CT: A case report.
Melanoma
A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors.
Melanoma
Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.
Melanoma
Photodynamic Therapy of Melanoma B16 with Chlorin E6 Conjugated with a PSMA-Ligand.
Melanoma
Prostate-specific membrane antigen expression in melanoma metastases.
Memory Disorders
NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.
Memory Disorders
NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.
Memory Disorders
NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.
Meningomyelocele
Role of parental folate pathway single nucleotide polymorphisms in altering the susceptibility to neural tube defects in South India.
Mesothelioma
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Mesothelioma
Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma.
Mesothelioma, Malignant
Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma.
Metabolic Syndrome
Dissecting the role of Folr1 and Folh1 genes in the pathogenesis of metabolic syndrome in spontaneously hypertensive rats.
Multiple Myeloma
Image of the Month: Multifocal 68Ga Prostate-Specific Membrane Antigen Ligand Uptake in the Skeleton in a Man With Both Prostate Cancer and Multiple Myeloma.
Multiple Sclerosis
Dose-dependent inhibition of GCPII to prevent and treat cognitive impairment in the EAE model of multiple sclerosis.
Multiple Sclerosis
Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition.
Multiple Sclerosis
Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.
Neoplasm Metastasis
(68)Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer.
Neoplasm Metastasis
18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy.
Neoplasm Metastasis
68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
Neoplasm Metastasis
68-gallium Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Detects Rare Testicular Metastasis from Prostate Cancer.
Neoplasm Metastasis
68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
Neoplasm Metastasis
68Ga-Prostate-Specific Membrane Antigen PET-Positive Paget Bone Disease With Metastatic Prostatic Carcinoma.
Neoplasm Metastasis
68Ga-Prostate-Specific Membrane Antigen PET/CT Uptake in Intraventricular Meningioma in the Choroid Plexus.
Neoplasm Metastasis
68Ga-Prostate-Specific Membrane Antigen-Avid Tubercular Lesions Mimicking Prostate Cancer Metastasis on Simultaneous Prostate-Specific Membrane Antigen PET/MRI.
Neoplasm Metastasis
68Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy.
Neoplasm Metastasis
68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy.
Neoplasm Metastasis
68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.
Neoplasm Metastasis
A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion.
Neoplasm Metastasis
A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients.
Neoplasm Metastasis
Abdominal Splenosis Mimicking Peritoneal Metastasis in Prostate-Specific Membrane Antigen PET/CT, Confirmed With Selective Spleen SPECT/CT.
Neoplasm Metastasis
Active Giant Cell Vasculitis Diagnosis with 68Ga PSMA PET/CT Imaging.
Neoplasm Metastasis
Advances in positron emission tomography applications for urologic cancers.
Neoplasm Metastasis
Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle.
Neoplasm Metastasis
Biochemical Recurrence of Prostate Cancer Presenting as Solitary Testicular Metastasis on 68Ga-Labeled Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography.
Neoplasm Metastasis
Bispecific radioligands targeting prostate-specific membrane antigen and gastrin-releasing peptide receptors on the surface of prostate cancer cells.
Neoplasm Metastasis
Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
Neoplasm Metastasis
Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?
Neoplasm Metastasis
Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Neoplasm Metastasis
Case Report: 18F-PSMA PET/CT May Improve the Clinical Management of Penile Metastases From Prostate Cancer.
Neoplasm Metastasis
Cerebellar Metastases From Prostate Cancer on 68Ga-PSMA PET/CT.
Neoplasm Metastasis
Circulating tumor cells mirror bone metastatic phenotype in prostate cancer.
Neoplasm Metastasis
Clinical Translation of Positive Metastases Identified on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging in the Management of De Novo Synchronous Oligometastatic Prostate Cancer.
Neoplasm Metastasis
Cloning and characterization of the prostate-specific membrane antigen promoter.
Neoplasm Metastasis
Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.
Neoplasm Metastasis
Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT.
Neoplasm Metastasis
Comparison of bone scintigraphy and Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography in the detection of bone metastases of prostate carcinoma.
Neoplasm Metastasis
Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer.
Neoplasm Metastasis
Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
Neoplasm Metastasis
Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
Neoplasm Metastasis
Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Neoplasm Metastasis
Correlations of 68Ga-PSMA PET/CT in the initial staging of prostate cancer patients.
Neoplasm Metastasis
Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review.
Neoplasm Metastasis
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.
Neoplasm Metastasis
Diagnostic performance of
Neoplasm Metastasis
Diagnostic Performance of ??Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis.
Neoplasm Metastasis
Dosimetric Analysis of the Short-Ranged Particle Emitter 161Tb for Radionuclide Therapy of Metastatic Prostate Cancer.
Neoplasm Metastasis
Early Detection of Bilateral Testicular Metastases From Prostatic Adenocarcinoma Using 68Ga-PSMA Ligand PET/CT.
Neoplasm Metastasis
Effects of Linker Modification on Tumor-to-Kidney Contrast of 68Ga-Labeled PSMA-Targeted Imaging Probes.
Neoplasm Metastasis
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
Neoplasm Metastasis
Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
Neoplasm Metastasis
External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study.
Neoplasm Metastasis
Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer.
Neoplasm Metastasis
Gastric GIST Incidentally Detected on 68Ga-PSMA-PET/CT: Correlation Between Functional Imaging and Histology.
Neoplasm Metastasis
Herniated Thoracic Spleen Mimicking Lung Metastasis on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in a Patient With Prostate Cancer.
Neoplasm Metastasis
Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis.
Neoplasm Metastasis
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Neoplasm Metastasis
Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
Neoplasm Metastasis
Identification of a novel microsatellite marker tightly linked to the KAI-1 gene for predicting prostate cancer progression.
Neoplasm Metastasis
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
Neoplasm Metastasis
Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?
Neoplasm Metastasis
Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?
Neoplasm Metastasis
Imaging for Metastasis in Prostate Cancer: A Review of the Literature.
Neoplasm Metastasis
Imaging of Prostate Cancer.
Neoplasm Metastasis
Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer.
Neoplasm Metastasis
In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells.
Neoplasm Metastasis
Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature.
Neoplasm Metastasis
Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
Neoplasm Metastasis
Is 177Lu-PSMA an effective treatment modality for mCRPC patients with bone and visceral metastasis?
Neoplasm Metastasis
Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer.
Neoplasm Metastasis
Machine Learning Facilitates Hotspot Classification in PSMA-PET/CT with Nuclear Medicine Specialist Accuracy.
Neoplasm Metastasis
Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy.
Neoplasm Metastasis
Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer.
Neoplasm Metastasis
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.
Neoplasm Metastasis
New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen.
Neoplasm Metastasis
New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
Neoplasm Metastasis
Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments.
Neoplasm Metastasis
Novel ?- and ?-Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen.
Neoplasm Metastasis
Nuclear Medicine Imaging of Prostate Cancer.
Neoplasm Metastasis
Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers.
Neoplasm Metastasis
Optimization of Labeling PSMA(HBED) with Ethanol-Postprocessed (68)Ga and Its Quality Control Systems.
Neoplasm Metastasis
Pancreatic Ductal Adenocarcinoma With High Radiotracer Uptake in 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Neoplasm Metastasis
Patterns of Lymph Node Failure in Patients With Recurrent Prostate Cancer Postradical Prostatectomy and Implications for Salvage Therapies.
Neoplasm Metastasis
Penile Metastasis from Prostate Cancer Presenting as Malignant Priapism Detected Using Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
Neoplasm Metastasis
Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection.
Neoplasm Metastasis
Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis.
Neoplasm Metastasis
PET imaging in urology: a rapidly growing successful collaboration.
Neoplasm Metastasis
Potential impact of 68Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning.
Neoplasm Metastasis
Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.
Neoplasm Metastasis
Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
Neoplasm Metastasis
Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA).
Neoplasm Metastasis
ProstaScint(R) Scan: Contemporary Use in Clinical Practice.
Neoplasm Metastasis
Prostate Cancer Imaging with Novel PET Tracers.
Neoplasm Metastasis
Prostate cancer nodal oligometastasis accurately assessed using prostate-specific membrane antigen positron emission tomography-computed tomography and confirmed histologically following robotic-assisted lymph node dissection.
Neoplasm Metastasis
Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
Neoplasm Metastasis
Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases.
Neoplasm Metastasis
Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice.
Neoplasm Metastasis
Prostate-specific membrane antigen expression in melanoma metastases.
Neoplasm Metastasis
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers.
Neoplasm Metastasis
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
Neoplasm Metastasis
Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond.
Neoplasm Metastasis
Prostate-Specific Membrane Antigen PET for Assessment of Primary and Recurrent Prostate Cancer with Histopathology as Reference Standard: A Systematic Review and Meta-Analysis.
Neoplasm Metastasis
Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis.
Neoplasm Metastasis
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer.
Neoplasm Metastasis
Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer.
Neoplasm Metastasis
Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression.
Neoplasm Metastasis
PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma.
Neoplasm Metastasis
PSMA Theranostics: Current Status and Future Directions.
Neoplasm Metastasis
Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Neoplasm Metastasis
Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
Neoplasm Metastasis
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy.
Neoplasm Metastasis
Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
Neoplasm Metastasis
Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review.
Neoplasm Metastasis
Salvage surgery for nodal recurrent prostate cancer.
Neoplasm Metastasis
Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Neoplasm Metastasis
Soft tissue metastasis of the penis detected by copper-64 labeled prostate-specific membrane antigen positron emission tomography (64Cu-PSMA PET/CT) in a patient with prostate cancer.
Neoplasm Metastasis
Solitary castrate-resistant prostate cancer metastasis to adrenal gland with concordant intense avidity on PSMA and FDG PET.
Neoplasm Metastasis
Spinal Tuberculosis Mimicking as Prostate Cancer Metastases in Ga-68 Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography.
Neoplasm Metastasis
Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
Neoplasm Metastasis
Subacute Cerebellar Infarction With Uptake on 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Neoplasm Metastasis
Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer.
Neoplasm Metastasis
Targeted Inhibition of Prostate Cancer Metastases with an RNA Aptamer to Prostate-specific Membrane Antigen.
Neoplasm Metastasis
Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers.
Neoplasm Metastasis
Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
Neoplasm Metastasis
The emergence of radioimmunoscintigraphy for prostate cancer.
Neoplasm Metastasis
The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
Neoplasm Metastasis
The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study.
Neoplasm Metastasis
The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate.
Neoplasm Metastasis
The potential of PSMA-targeted alpha therapy in the management of prostate cancer.
Neoplasm Metastasis
The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
Neoplasm Metastasis
The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.
Neoplasm Metastasis
The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
Neoplasm Metastasis
Unusual Case of Diffuse Penile Metastasis of Prostate Cancer on 68Ga PSMA PET/CT Imaging and 177Lu PSMA Posttherapy Scintigraphy.
Neoplasm Metastasis
Unusual presentation of castrate-resistant prostate cancer with urethral and inguinal nodal metastasis.
Neoplasm Metastasis
Upcoming Role of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Detecting Occult Metastases in Prostate Cancer.
Neoplasm Metastasis
Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia.
Neoplasm Metastasis
Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Neoplasm Metastasis
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.
Neoplasm Metastasis
Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
Neoplasm Micrometastasis
(2S)-2-(3-(1-Carboxy-5-(4-[211At]astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-Targeted ?-Particle Radiopharmaceutical Therapy.
Neoplasm Micrometastasis
Prostate specific membrane antigen (PSM) is expressed in various human tissues: implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread.
Neoplasm Micrometastasis
Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis.
Neoplasm Micrometastasis
Significance of micrometastases in prostate cancer.
Neoplasm Micrometastasis
The application of the RT-PCR method for the staging of the prostate cancer progression.
Neoplasms
(111)In-capromab pendetide: the evolution of prostate specific membrane antigen and the nuclear imaging of its (111)in-labelled murine antibody in the evaluation of prostate cancer.
Neoplasms
(177)Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.
Neoplasms
(64)Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer.
Neoplasms
(68)Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging.
Neoplasms
11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase).
Neoplasms
123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
Neoplasms
177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor.
Neoplasms
18F-DCFPyL PET/CT in Oncocytoma.
Neoplasms
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
Neoplasms
18F-Labeled Small-Molecule and Low-Molecular-Weight PET Tracers for the Noninvasive Detection of Cancer.
Neoplasms
33 increased sensitivity in the detection of circulating prostatic tumor cells in peripheral blood after immunobead enrichment and RT-PCR for prostate specific membrane antigen (PSMA) mRNA
Neoplasms
68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
Neoplasms
68Ga-Prostate-Specific Membrane Antigen PET/CT in Cholangiocarcinoma: A Potential Biomarker for Targeted Radioligand Therapy?
Neoplasms
68Ga-Prostate-Specific Membrane Antigen PET/CT in Sinonasal Glomangiopericytoma-Exploring Theranostic Avenues!
Neoplasms
68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.
Neoplasms
68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future?
Neoplasms
68Ga-PSMA PET/CT in the evaluation of locally advanced and metastatic breast cancer, a single center experience.
Neoplasms
68Ga-PSMA PET/CT Scan on Postoperative Assessment of Sinonasal Glomangiopericytoma.
Neoplasms
68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability.
Neoplasms
68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study.
Neoplasms
68Ga-PSMA-Ligand PET/CT Uptake in Anthracosilicosis.
Neoplasms
99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer.
Neoplasms
A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Neoplasms
A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention.
Neoplasms
A case of hepatic focal nodular hyperplasia mimicking hepatocellular carcinoma identified on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography.
Neoplasms
A Case of Well-differentiated Hepatocellular Carcinoma Identified on Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
Neoplasms
A deformable multimodal image registration using PET/CT and TRUS for intraoperative focal prostate brachytherapy.
Neoplasms
A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen.
Neoplasms
A dimeric Peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
Neoplasms
A Low Molecular Weight PSMA-Based Fluorescent Imaging Agent for Cancer.
Neoplasms
A Novel Screening Method to Establish Tumor-targeting Antibodies Reliable for Drug Delivery System.
Neoplasms
A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors.
Neoplasms
A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma.
Neoplasms
A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile.
Neoplasms
A PSMA-targeted theranostic agent for photodynamic therapy.
Neoplasms
A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.
Neoplasms
A ribonucleoprotein octamer for targeted siRNA delivery.
Neoplasms
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals.
Neoplasms
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.
Neoplasms
Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer.
Neoplasms
Activatable fluorescent cys-diabody conjugated with indocyanine green derivative: consideration of fluorescent catabolite kinetics on molecular imaging.
Neoplasms
Acute statin treatment improves antibody accumulation in EGFR- and PSMA-expressing tumors.
Neoplasms
Advancement of MR and PET/MR in Prostate Cancer.
Neoplasms
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Neoplasms
Advances in Targeted Alpha Therapy for Prostate Cancer.
Neoplasms
An 89Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients.
Neoplasms
An Anti-PSMA Bivalent Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Imaging and Therapy.
Neoplasms
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer.
Neoplasms
An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay.
Neoplasms
Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients.
Neoplasms
Analysis of prostate-specific membrane antigen splice variants in LNCap cells.
Neoplasms
Androgen receptor overexpression in prostate cancer in type 2 diabetes.
Neoplasms
Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle.
Neoplasms
Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses.
Neoplasms
Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells.
Neoplasms
Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.
Neoplasms
Aptamer:toxin conjugates that specifically target prostate tumor cells.
Neoplasms
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Neoplasms
Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature.
Neoplasms
Biochemical characterization of human glutamate carboxypeptidase III.
Neoplasms
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.
Neoplasms
Biosensing with Virus Electrode Hybrids.
Neoplasms
Boranophosphate siRNA-aptamer chimeras for tumor-specific downregulation of cancer receptors and modulators.
Neoplasms
Bridging the Metabolic Parallels Between Neurological Diseases and Cancer.
Neoplasms
Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?
Neoplasms
Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?
Neoplasms
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.
Neoplasms
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.
Neoplasms
Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Neoplasms
Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase.
Neoplasms
Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture.
Neoplasms
Chemically synthesized molecules with the targeting and effector functions of antibodies.
Neoplasms
Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads.
Neoplasms
Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI(3)kinase/AKT/Bcl-X(L) Activation and CD8(+) T Cell-mediated Tumor Eradication.
Neoplasms
Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
Neoplasms
Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer.
Neoplasms
Clinical Molecular Imaging with Radiotracers: Current Status.
Neoplasms
Clinical trials of cancer therapies targeting prostate-specific membrane antigen.
Neoplasms
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.
Neoplasms
Clinical Utility of 68Ga-Prostate-Specific Membrane Antigen PET/CT Scan on Postoperative Assessment of Juvenile Nasal Angiofibroma.
Neoplasms
Clinical utility of genetic variants of glutamate carboxypeptidase II in predicting breast cancer and prostate cancer risk.
Neoplasms
Co-administration of a DNA vaccine encoding the prostate specific membrane antigen and CpG oligodeoxynucleotides suppresses tumor growth.
Neoplasms
Co-Delivery of Docetaxel and p44/42 MAPK siRNA Using PSMA Antibody-Conjugated BSA-PEI Layer-by-Layer Nanoparticles for Prostate Cancer Target Therapy.
Neoplasms
Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute.
Neoplasms
Combined impact of polymorphism of folate metabolism genes; glutamate carboxypeptidase, methylene tetrahydrofolate reductase and methionine synthase reductase on breast cancer susceptibility in kashmiri women.
Neoplasms
Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).
Neoplasms
Comparative Findings Between 68Ga-PSMA and 18F-FDG PET/CT for Hepatocellular Carcinoma
Neoplasms
Comparative immuno-Cerenkov luminescence and -PET imaging enables detection of PSMA+ tumors in mice using 64Cu-radiolabeled monoclonal antibodies.
Neoplasms
Comparison between 177Lu-iPSMA and 225Ac-iPSMA dosimetry at a cellular level in an animal bone metastasis model.
Neoplasms
Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT.
Neoplasms
Comparison of 68Ga-PSMA PET/CT and Contrast-Enhanced MRI on Residual Disease Assessment of Juvenile Nasal Angiofibroma.
Neoplasms
Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities.
Neoplasms
Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml.
Neoplasms
Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
Neoplasms
Comprehensive Evaluation of Prostate-Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.
Neoplasms
Conformational and SAR analysis of NAALADase and PSMA inhibitors.
Neoplasms
Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer.
Neoplasms
Correlation Between PSMA and VEGF Expression as Markers for LNCaP Tumor Angiogenesis.
Neoplasms
Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.
Neoplasms
Correlations of the 68Ga-PSMA PET/CT derived primary prostate tumor PSMA expression parameters and metastatic patterns in patients with Gleason Score >7 prostate cancer.
Neoplasms
Correspondence re: Ghosh A and Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539, 2004.
Neoplasms
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.
Neoplasms
Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies.
Neoplasms
Demonstration of 68Ga-prostate-specific Membrane Antigen Uptake in Metastatic Pancreatic Neuroendocrine Tumor.
Neoplasms
Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
Neoplasms
Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Neoplasms
Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma.
Neoplasms
Detection of minimal disease in patients with solid tumors.
Neoplasms
Detection of Prostate Specific Membrane Antigen at Picomolar Levels Using Biocatalysis Coupled to Assisted Ion Transfer Voltammetry at a Liquid-Organogel Microinterface Array.
Neoplasms
Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium.
Neoplasms
Detection Rate of 68Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy.
Neoplasms
Development and Screening of a Series of Antibody-Conjugated and Silica-Coated Iron Oxide Nanoparticles for Targeting the Prostate-Specific Membrane Antigen.
Neoplasms
Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen.
Neoplasms
Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Neoplasms
Development of tumor-targeted near infrared probes for fluorescence guided surgery.
Neoplasms
Diagnostic accuracy of 68 Ga-PSMA PET/MRI and multiparametric MRI in detecting index tumours in radical prostatectomy specimen.
Neoplasms
Diagnostic performance of 18F-DCFPyL positron emission tomography/computed tomography for biochemically recurrent prostate cancer and change-of-management analysis.
Neoplasms
Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study.
Neoplasms
Diagnostic potential of serum extracellular vesicles expressing prostate-specific membrane antigen in urologic malignancies.
Neoplasms
Differences in the expression of telomerase and prostate-specific membrane antigen in non-advanced prostatic cancer.
Neoplasms
Different Appearances of 3 Malignancies in 68Ga-PSMA-11 Versus 18F-FDG PET/CT.
Neoplasms
Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma.
Neoplasms
Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients.
Neoplasms
Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Neoplasms
Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages.
Neoplasms
DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening.
Neoplasms
Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts.
Neoplasms
Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy.
Neoplasms
Dynamic 68Ga-PSMA-11 PET/CT for the Primary Evaluation of Localized Renal Mass: A Prospective Study.
Neoplasms
Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen.
Neoplasms
Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
Neoplasms
Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond.
Neoplasms
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.
Neoplasms
Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation.
Neoplasms
Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs.
Neoplasms
Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies.
Neoplasms
Enzymatic radiosynthesis of a 18F-Glu-Ureido-Lys ligand for the prostate-specific membrane antigen (PSMA).
Neoplasms
Evaluation of 68Ga-Glutamate Carboxypeptidase II Ligand Positron Emission Tomography for Clinical Molecular Imaging of Atherosclerotic Plaque Neovascularization.
Neoplasms
Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.
Neoplasms
Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using 68Ga-PSMA PET/CT.
Neoplasms
Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Neoplasms
Expression of glutamate carboxypeptidase II in human brain.
Neoplasms
Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Neoplasms
Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization.
Neoplasms
Expression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and its Correlation with Tumor Grade.
Neoplasms
Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance.
Neoplasms
Expression of prostate-specific membrane antigen in normal and malignant human tissues.
Neoplasms
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.
Neoplasms
Expression of prostate-specific membrane antigen in renal cortical tumors.
Neoplasms
Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Neoplasms
Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature.
Neoplasms
Formulation and dosage of therapeutic nanosuspension for active targeting of docetaxel (WO 2014210485A1).
Neoplasms
From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug Development.
Neoplasms
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
Neoplasms
Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
Neoplasms
Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers.
Neoplasms
Gastric Metastasis of Prostate Cancer as an Unusual Presentation Using 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Neoplasms
GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond.
Neoplasms
GCPII Imaging and Cancer.
Neoplasms
GCPII Variants, Paralogs and Orthologs.
Neoplasms
Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay.
Neoplasms
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Neoplasms
Glutamyl hydrolase. pharmacological role and enzymatic characterization.
Neoplasms
Heterobivalent agents targeting PSMA and integrin-?v?3.
Neoplasms
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.
Neoplasms
High expression of PSM-E correlated with tumor grade in prostate cancer: A new alternatively spliced variant of prostate-specific membrane antigen.
Neoplasms
Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device.
Neoplasms
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
Neoplasms
Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
Neoplasms
Imaging for Response Assessment in Cancer Clinical Trials.
Neoplasms
Imaging of prostate cancer: optimizing affinity to prostate specific membrane antigen by spacer modifications in a tumor spheroid model.
Neoplasms
Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
Neoplasms
Imaging of Prostate-Specific Membrane Antigen Using [(18)F]DCFPyL.
Neoplasms
Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer.
Neoplasms
Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.
Neoplasms
Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Neoplasms
Immunohistochemical Reactivity of Prostate-Specific Membrane Antigen in Salivary Gland Tumors.
Neoplasms
Improved Cancer Targeting by Multimerizing Aptamers on Nanoscaffolds.
Neoplasms
Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker.
Neoplasms
In vitro and in vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-conjugated Antibody to Prostate-specific Membrane Antigen.
Neoplasms
In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Neoplasms
In Vivo Demonstration of PSMA Expression in Adenocarcinoma Urinary Bladder Using 68Ga-PSMA 11 PET/CT.
Neoplasms
In vivo targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two ?-linked glutamate residues at the COOH terminus.
Neoplasms
In Vivo Visualization of Prostate-Specific Membrane Antigen in Adenoid Cystic Carcinoma of the Salivary Gland.
Neoplasms
Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer.
Neoplasms
Incidental finding of ileal gastrointestinal stromal tumour during prostate cancer staging with prostate-specific membrane antigen scan.
Neoplasms
Incidental Prostate-Specific Membrane Antigen Uptake in a Peripheral Nerve Sheath Tumor.
Neoplasms
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.
Neoplasms
Induction of PSMA and Internalization of an anti-PSMA mAb in the Vascular Compartment.
Neoplasms
Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA.
Neoplasms
Inhibitor-GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles.
Neoplasms
Initial Experience with Volumetric (68)Ga-PSMA I&T PET/CT for Assessment of Whole-body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.
Neoplasms
Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.
Neoplasms
Introduction of Novel Structured Reporting Systems for PET Radiotracers with Potential Theranostic Applications.
Neoplasms
Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain: [La ketamine et un inhibiteur N-acetylaspartylglutamate peptidase exercent une analgesie sur la douleur du cancer des os].
Neoplasms
Lactate Dehydrogenase A Depletion Alters MyC-CaP Tumor Metabolism, Microenvironment, and CAR T Cell Therapy.
Neoplasms
Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells.
Neoplasms
Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues.
Neoplasms
Long-Circulating Prostate-Specific Membrane Antigen-Targeted NIR Phototheranostic Agent.
Neoplasms
Long-Term Stability Monitoring of Printed Proteins on Paper-Based Membranes.
Neoplasms
Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.
Neoplasms
Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging.
Neoplasms
M13 phage-functionalized single-walled carbon nanotubes as nanoprobes for second near-infrared window fluorescence imaging of targeted tumors.
Neoplasms
MDM2 and PSMA Play Inhibitory Roles in Metastatic Breast Cancer Cells Through Regulation of Matrix Metalloproteinases.
Neoplasms
Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy-Do Different Software Solutions Deliver Comparable Results?
Neoplasms
Metal-Based PSMA Radioligands.
Neoplasms
Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy.
Neoplasms
Metastasized 18F-DCFPyL-Negative Prostatic Adenocarcinoma Without Neuroendocrine Differentiation.
Neoplasms
Microfluidic-integrated patterned ITO immunosensor for rapid detection of prostate-specific membrane antigen biomarker in prostate cancer.
Neoplasms
Missing Selectivity of Targeted 4?-Phorbol Prodrugs Expected to be Potential Chemotherapeutics.
Neoplasms
Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands.
Neoplasms
Molecular Imaging in Oncology Using Positron Emission Tomography.
Neoplasms
Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA.
Neoplasms
Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
Neoplasms
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.
Neoplasms
Monoclonal antibodies and prostate-specific membrane antigen.
Neoplasms
Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.
Neoplasms
Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer--focus on prostate-specific membrane antigen?
Neoplasms
Monosodium glutamate reduces 68Ga-PSMA-11 uptake in salivary glands and kidneys in preclinical prostate cancer model.
Neoplasms
More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.
Neoplasms
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy.
Neoplasms
N-Substituted Glutamyl Sulfonamides as Inhibitors of Glutamate Carboxypeptidase II (GCP2).
Neoplasms
Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer.
Neoplasms
Nanobody-displaying porous silicon nanoparticles for the co-delivery of siRNA and doxorubicin.
Neoplasms
Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues.
Neoplasms
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Neoplasms
Neuroendocrine differentiation of prostate cancer leads to PSMA suppression.
Neoplasms
Noninvasive Imaging of PSMA in Prostate Tumors with (89)Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives.
Neoplasms
Novel 177Lu-labeled Albumin-binder-conjugated PSMA-targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-kidney Absorbed Dose Ratio.
Neoplasms
Novel Non-Congeneric Derivatives of the Choline Kinase Alpha Inhibitor ICL-CCIC-0019.
Neoplasms
Novel solid-phase strategy for the synthesis of ligand-targeted fluorescent-labelled chelating peptide conjugates as a theranostic tool for cancer.
Neoplasms
Nuclear Medicine Imaging of Prostate Cancer.
Neoplasms
Nuclear Medicine Imaging Procedures in Oncology.
Neoplasms
One-step 18F-labeling and preclinical evaluation of prostate specific membrane antigen trifluoroborate probes for cancer imaging.
Neoplasms
Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.
Neoplasms
Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility.
Neoplasms
Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection.
Neoplasms
Peptide-Based Radiopharmaceuticals for Molecular Imaging of Prostate Cancer.
Neoplasms
PET imaging in urology: a rapidly growing successful collaboration.
Neoplasms
PET imaging quantifying 68Ga-PSMA-11 uptake in metastatic colorectal cancer.
Neoplasms
PET/CT in the management of differentiated thyroid cancer.
Neoplasms
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer.
Neoplasms
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
Neoplasms
Photodynamic Therapy Is an Effective Adjuvant Therapy for Image-Guided Surgery in Prostate Cancer.
Neoplasms
Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour.
Neoplasms
Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.
Neoplasms
Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.
Neoplasms
Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
Neoplasms
Positron-emission tomography imaging in urological oncology: Current aspects and developments.
Neoplasms
Potential effective inhibitory compounds against Prostate Specific Membrane Antigen (PSMA): A molecular docking and molecular dynamics study.
Neoplasms
Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness.
Neoplasms
Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with
Neoplasms
Pre-therapeutic comparative dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMAI&T in patients with metastatic castration resistant prostate cancer (mCRPC).
Neoplasms
Preclinical assessment of 68 Ga-PSMA-617 entrapped in a microemulsion delivery system for applications in prostate cancer PET/CT imaging.
Neoplasms
Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
Neoplasms
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
Neoplasms
Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
Neoplasms
Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
Neoplasms
Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease.
Neoplasms
Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use.
Neoplasms
Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA).
Neoplasms
Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity.
Neoplasms
Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells.
Neoplasms
Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis.
Neoplasms
Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Neoplasms
Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis.
Neoplasms
Prostate specific membrane antigen (PSMA) in urothelial cell carcinoma (UCC) is associated with tumor grading and staging.
Neoplasms
Prostate Specific Membrane Antigen (PSMA) Regulates Angiogenesis Independently of VEGF during Ocular Neovascularization.
Neoplasms
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Neoplasms
Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer.
Neoplasms
Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy.
Neoplasms
Prostate-specific membrane antigen (PSMA) immunoexpression in the neovasculature of colorectal carcinoma in Egyptian patients.
Neoplasms
Prostate-Specific Membrane Antigen (PSMA) Promotes Angiogenesis of Glioblastoma Through Interacting With ITGB4 and Regulating NF-?B Signaling Pathway.
Neoplasms
Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.
Neoplasms
Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers.
Neoplasms
Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
Neoplasms
Prostate-specific membrane antigen and its truncated form PSM'.
Neoplasms
Prostate-specific membrane antigen and other prostatic tumor markers on the horizon.
Neoplasms
Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.
Neoplasms
Prostate-specific membrane antigen as a target for cancer imaging and therapy.
Neoplasms
Prostate-specific membrane antigen directed selective thrombotic infarction of tumors.
Neoplasms
Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Neoplasms
Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging.
Neoplasms
Prostate-Specific Membrane Antigen Expression in Neovasculature of Glioblastoma Multiforme.
Neoplasms
Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
Neoplasms
Prostate-specific membrane antigen expression in regeneration and repair.
Neoplasms
Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.
Neoplasms
Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond.
Neoplasms
Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing?
Neoplasms
Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.
Neoplasms
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
Neoplasms
Prostate-specific membrane antigen is produced in tumor-associated neovasculature.
Neoplasms
Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane.
Neoplasms
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.
Neoplasms
Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction.
Neoplasms
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Neoplasms
Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Neoplasms
Prostate-specific Membrane Antigen-expressing Hepatic Lesion: Metastatic or Hepatocellular Carcinoma.
Neoplasms
Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.
Neoplasms
Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin.
Neoplasms
Prostate-specific membrane antigen.
Neoplasms
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma.
Neoplasms
PSMA Expression in 122 Treatment Naive Glioma Patients Related to Tumor Metabolism in 11C-Methionine PET and Survival.
Neoplasms
PSMA Expression in Tumor Neovasculature Endothelial Cells of Follicular Thyroid Adenoma as Identified by Molecular Imaging Using 68Ga-PSMA Ligand PET/CT.
Neoplasms
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome.
Neoplasms
PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management.
Neoplasms
PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression.
Neoplasms
PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses.
Neoplasms
PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking.
Neoplasms
PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.
Neoplasms
PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.
Neoplasms
PSMA-targeted dendrimers: a patent evaluation (WO2012078534).
Neoplasms
PSMA-targeted melanin-like nanoparticles as a multifunctional nanoplatform for prostate cancer theranostics.
Neoplasms
PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.
Neoplasms
Pulmonary Opacities and Bronchiectasis Avid on 68Ga-PSMA PET.
Neoplasms
Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.
Neoplasms
Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy.
Neoplasms
Quantum dots for in vivo molecular and cellular imaging.
Neoplasms
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Neoplasms
Radiomics Analysis for 177Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer-A Model Based on Clinical Example.
Neoplasms
Radiopharmaceutical Therapy.
Neoplasms
Radium and other alpha emitters in prostate cancer.
Neoplasms
Re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028.
Neoplasms
Re: Isabel Rauscher, Charlotte Düwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol 2018;73:656-61: Clinical Significance of Prostate-specific Membrane Antigen Immunohistochemistry and Role of the Uropathologists.
Neoplasms
Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomized, Multicenter Study. Lancet 2020;395:1208-16.
Neoplasms
Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. Lancet 2020;395:1208-16: PSMA Positron Emission Tomography: One Tracer Fixes Them All!
Neoplasms
Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer.
Neoplasms
Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals.
Neoplasms
Recent advances of bispecific antibodies in solid tumors.
Neoplasms
Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.
Neoplasms
Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells.
Neoplasms
Rectal Carcinoma on 68Ga-PSMA PET/CT.
Neoplasms
Recurrent Brain Metastasis of Triple Negative Breast Cancer With High Uptake in 68Ga-PSMA-11 PET/CT.
Neoplasms
Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Neoplasms
Renal-type clear cell carcinoma of prostate: A case report and review of literature.
Neoplasms
Repeatability of 68Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
Neoplasms
Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028: Despite its Slightly Limited Specificity, Prostate-specific Membrane Antigen Imaging is Still a Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
Neoplasms
Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy.
Neoplasms
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.
Neoplasms
Robotic real-time near infrared targeted fluorescence imaging in a murine model of prostate cancer: a feasibility study.
Neoplasms
Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
Neoplasms
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Neoplasms
Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA).
Neoplasms
Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens.
Neoplasms
Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays.
Neoplasms
Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors.
Neoplasms
Small Molecule, Multimodal, [18F]-PET and Fluorescence Imaging Agent Targeting Prostate-Specific Membrane Antigen: First-in-Human Study.
Neoplasms
SPECT-CT Imaging with [99mTc]PSMA-T4 in patients with Recurrent Prostate Cancer.
Neoplasms
Structural and Biochemical Characterization of a Novel Aminopeptidase from Human Intestine.
Neoplasms
Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer.
Neoplasms
Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III.
Neoplasms
Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors.
Neoplasms
Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate.
Neoplasms
Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.
Neoplasms
Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
Neoplasms
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.
Neoplasms
Synthesis and Binding of a Novel PSMA-specific Conjugate.
Neoplasms
Synthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen.
Neoplasms
Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of PSMA and Hypoxia for Prostate Cancer.
Neoplasms
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).
Neoplasms
Synthesis of modular dipeptide mimetics on the basis of diazabicycloalkanes and derivatives thereof with sulphur containing side chains.
Neoplasms
Synthesis of Symmetrical Tetrameric Conjugates of the Radiolanthanide Chelator DOTPI for Application in Endoradiotherapy by Means of Click Chemistry.
Neoplasms
Synthesis, chemical and biochemical characterization of Lu2O3-iPSMA nanoparticles activated by neutron irradiation.
Neoplasms
T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.
Neoplasms
Targeted ?-therapy in non-prostate malignancies.
Neoplasms
Targeted ?-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.
Neoplasms
Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen).
Neoplasms
Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Neoplasms
Targeted Radiosensitizers for MR-Guided Radiation Therapy of Prostate Cancer.
Neoplasms
Targeted, Activatable, In Vivo Fluorescence Imaging of Prostate-Specific Membrane Antigen (PSMA) Positive Tumors Using the Quenched Humanized J591 Antibody-Indocyanine Green (ICG) Conjugate.
Neoplasms
Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers.
Neoplasms
Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging.
Neoplasms
Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.
Neoplasms
Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy.
Neoplasms
Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
Neoplasms
Targeting prostate-specific membrane antigen in cancer therapy: can molecular medicine be brought to the surface?
Neoplasms
Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
Neoplasms
Targeting thapsigargin towards tumors.
Neoplasms
Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.
Neoplasms
Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
Neoplasms
The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies.
Neoplasms
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer.
Neoplasms
The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers.
Neoplasms
The clinical role of prostate-specific membrane antigen (PSMA).
Neoplasms
The effects of specific expression of apoptin under the control of PSES and PSA promoter on cell death and apoptosis of LNCaP cells.
Neoplasms
The expression of prostate-specific membrane antigen in peripheral blood leukocytes.
Neoplasms
The frequency of thyroid incidental findings and risk of malignancy detected by 68Ga-labeled prostate-specific membrane antigen PET/CT in prostate cancer.
Neoplasms
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy.
Neoplasms
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways.
Neoplasms
The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer.
Neoplasms
The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
Neoplasms
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Neoplasms
Theranostics in oncology: What radiologists want to know.
Neoplasms
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
Neoplasms
Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.
Neoplasms
Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents.
Neoplasms
Triple synchronous tumours of the urinary system with different histologies: a case report.
Neoplasms
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
Neoplasms
Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Neoplasms
Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?
Neoplasms
Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer.
Neoplasms
Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas.
Neoplasms
Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications.
Neoplasms
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland.
Neoplasms
Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA).
Neoplasms
Use of oligonucleotide aptamer ligands to modulate the function of immune receptors.
Neoplasms
Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context.
Neoplasms
Using RNA aptamers and the proximity ligation assay for the detection of cell surface antigens.
Neoplasms
Vaccine therapy for prostate cancer.
Neoplasms
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
Neoplasms
Well-Differentiated Thyroid Cancer Neovasculature Expresses Prostate-Specific Membrane Antigen-a Possible Novel Therapeutic Target.
Neoplasms
What's in a Label? Radioimmunotherapy for Metastatic Prostate Cancer.
Neoplasms
[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).
Neoplasms
[(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
Neoplasms
[68 Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma.
Neoplasms
[Clinical significance of detecting circulating cancer cells in patients with solid malignancies]
Neoplasms
[Prostate specific membrane antigen (PSMA) as a role of tumor marker]
Neoplasms
[Prostate-specific membrane antigen. A new sensitive molecular indicator in metastasizing prostatic cancer]
Neoplasms
[Radionuclide therapy and diagnostics in urology].
Neoplasms
[Related biomarkers in the diagnosis of prostate cancer].
Neoplasms
[Reports of prostate needle biopsies-what pathologists provide and urologists want].
Neoplasms
[Significance of current bio- and molecular-markers in urological cancers]
Neoplasms, Germ Cell and Embryonal
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Neoplasms, Glandular and Epithelial
68Ga-PSMA-Ligand PET/CT Uptake in Anthracosilicosis.
Neoplasms, Second Primary
Gastric GIST Incidentally Detected on 68Ga-PSMA-PET/CT: Correlation Between Functional Imaging and Histology.
Neoplastic Cells, Circulating
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.
Neoplastic Cells, Circulating
Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer.
Neoplastic Cells, Circulating
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Neoplastic Cells, Circulating
Microfluidic-integrated patterned ITO immunosensor for rapid detection of prostate-specific membrane antigen biomarker in prostate cancer.
Neoplastic Cells, Circulating
Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease.
Neoplastic Cells, Circulating
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
Neoplastic Cells, Circulating
Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy.
Neoplastic Cells, Circulating
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Neoplastic Cells, Circulating
[Clinical significance of detecting circulating cancer cells in patients with solid malignancies]
Nerve Sheath Neoplasms
Incidental Prostate-Specific Membrane Antigen Uptake in a Peripheral Nerve Sheath Tumor.
Nervous System Diseases
Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities.
Nervous System Diseases
Design of NAALADase inhibitors: a novel neuroprotective strategy.
Nervous System Diseases
Development of a High-Throughput Fluorescence Polarization Assay to Identify Novel Ligands of Glutamate Carboxypeptidase II.
Nervous System Diseases
Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer.
Nervous System Diseases
Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.
Nervous System Diseases
Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis.
Nervous System Diseases
N-Substituted Glutamyl Sulfonamides as Inhibitors of Glutamate Carboxypeptidase II (GCP2).
Nervous System Diseases
NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.
Nervous System Diseases
Pharmacokinetics and Pharmacodynamics of the Glutamate Carboxypeptidase II Inhibitor 2-MPPA Show Prolonged Alleviation of Neuropathic Pain through an Indirect Mechanism.
Nervous System Diseases
Progress in the discovery and development of glutamate carboxypeptidase II inhibitors.
Nervous System Diseases
Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.
Nervous System Diseases
Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors.
Nervous System Diseases
Unprecedented Binding Mode of Hydroxamate-Based Inhibitors of Glutamate Carboxypeptidase II: Structural Characterization and Biological Activity.
Neural Tube Defects
Association of FOLH1, DHFR, and MTHFR gene polymorphisms with susceptibility of Neural Tube Defects: A case control study from Eastern India.
Neural Tube Defects
Glutamate carboxypeptidase II gene polymorphisms and neural tube defects in a high-risk Chinese population.
Neural Tube Defects
The H475Y polymorphism in the glutamate carboxypeptidase II gene increases plasma folate without affecting the risk for neural tube defects in humans.
Neural Tube Defects
The maternal folate hydrolase gene polymorphism is associated with neural tube defects in a high-risk Chinese population.
Neuralgia
Discovery of a para-Acetoxy-benzyl Ester Prodrug of a Hydroxamate-Based Glutamate Carboxypeptidase II Inhibitor as Oral Therapy for Neuropathic Pain.
Neuralgia
Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain.
Neuralgia
Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.
Neuralgia
N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
Neuralgia
ORALLY ACTIVE GCPII INHIBITOR, E2072, EXHIBITS SUSTAINED NERVE EXPOSURE AND ATTENUATES PERIPHERAL NEUROPATHY.
Neuralgia
Pharmacokinetics and Pharmacodynamics of the Glutamate Carboxypeptidase II Inhibitor 2-MPPA Show Prolonged Alleviation of Neuropathic Pain through an Indirect Mechanism.
Neuralgia
Reversible Disulfide Formation of the GCP-II Inhibitor E2072 Results in Prolonged Systemic Exposures In Vivo.
Neuralgia
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Neuralgia
The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.
Neurilemmoma
Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer.
Neurilemmoma
Prostate-Specific Membrane Antigen PET/CT Incidental Finding of a Schwannoma.
Neurodegenerative Diseases
Design and pharmacological activity of phosphinic acid based NAALADase inhibitors.
Neurodegenerative Diseases
Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity.
Neuroendocrine Tumors
An Impressive Approach in Nuclear Medicine: Theranostics.
Neuroendocrine Tumors
Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.
Neuroendocrine Tumors
Exciting Opportunities in Nuclear Medicine Imaging and Therapy.
Neuroendocrine Tumors
Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.
Neuroendocrine Tumors
Phosphinic Acid Functionalized Polyazacycloalkane Chelators for Radiodiagnostics and Radiotherapeutics: Unique Characteristics and Applications.
Neuroendocrine Tumors
Prostate-Specific Membrane Antigen (PSMA) Avid Pancreatic Neuroendocrine Tumor.
Neuroendocrine Tumors
Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT.
Neuroendocrine Tumors
The emerging value of 64Cu for molecular imaging and therapy.
Neurofibromatoses
Increased Prostate-Specific Membrane Antigen Uptake in Neurofibromatosis.
Obesity
Gene expression profile of peripheral blood mononuclear cells in mild to moderate obesity in dogs.
Osteosarcoma
Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma.
Pancreatic Neoplasms
Prostate-specific membrane antigen as a marker of pancreatic cancer cells.
Peripheral Nervous System Diseases
Design and pharmacological activity of phosphinic acid based NAALADase inhibitors.
Peripheral Nervous System Diseases
Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.
Peripheral Nervous System Diseases
Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury.
Peripheral Nervous System Diseases
ORALLY ACTIVE GCPII INHIBITOR, E2072, EXHIBITS SUSTAINED NERVE EXPOSURE AND ATTENUATES PERIPHERAL NEUROPATHY.
Peripheral Nervous System Diseases
Regulation of Glutamate Synthesis Via Inhibition of Glutamate Carboxypeptidase II (GCPII): An Effective Method to Treat Central and Peripheral Nervous System Disorders.
Peripheral Nervous System Diseases
Reversible Disulfide Formation of the GCP-II Inhibitor E2072 Results in Prolonged Systemic Exposures In Vivo.
Peripheral Nervous System Diseases
The Role of Glutamate in Diabetic and in Chemotherapy Induced Peripheral Neuropathies and its Regulation by Glutamate Carboxypeptidase II.
Pheochromocytoma
68Ga-Labeled Prostate-Specific Membrane Antigen Uptake in Pheochromocytoma: An Incidental Finding in PET/CT Scan.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Incidental Finding of Acute Lymphocytic Leukemia in a Prostate-Specific Membrane Antigen PET/CT.
Priapism
Penile Metastasis from Prostate Cancer Presenting as Malignant Priapism Detected Using Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
Prostatic Hyperplasia
Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Prostatic Hyperplasia
Monoclonal antibodies and prostate-specific membrane antigen.
Prostatic Hyperplasia
The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Prostatic Hyperplasia
The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma.
Prostatic Intraepithelial Neoplasia
Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Prostatic Intraepithelial Neoplasia
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Prostatic Neoplasms
'Image and treat': an individualized approach to urological tumors.
Prostatic Neoplasms
(111)In-capromab pendetide: the evolution of prostate specific membrane antigen and the nuclear imaging of its (111)in-labelled murine antibody in the evaluation of prostate cancer.
Prostatic Neoplasms
(177)Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.
Prostatic Neoplasms
(177)Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer.
Prostatic Neoplasms
(2S)-2-(3-(1-Carboxy-5-(4-[211At]astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-Targeted ?-Particle Radiopharmaceutical Therapy.
Prostatic Neoplasms
(64)Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer.
Prostatic Neoplasms
(68)Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
Prostatic Neoplasms
(68)Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block-Early or Too Early to Draw Conclusions?
Prostatic Neoplasms
(68)Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer.
Prostatic Neoplasms
(68)Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review.
Prostatic Neoplasms
(68)Ga-PSMA PET/CT in prostate cancer.
Prostatic Neoplasms
(68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer.
Prostatic Neoplasms
(68)Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with (223)Ra: Proof of Concept.
Prostatic Neoplasms
(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.
Prostatic Neoplasms
(68Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy.
Prostatic Neoplasms
(99m)Tc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients.
Prostatic Neoplasms
11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase).
Prostatic Neoplasms
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Prostatic Neoplasms
177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy.
Prostatic Neoplasms
177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney.
Prostatic Neoplasms
18 F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer.
Prostatic Neoplasms
18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.
Prostatic Neoplasms
18F-DCFPyL PET/CT Imaging in Patients with Biochemical Recurrence Prostate Cancer after Primary Local Therapy.
Prostatic Neoplasms
18F-DCFPyL PET/CT in a Single Large Metastasis With Prostate-Specific Antigen Level of 856 ng/mL.
Prostatic Neoplasms
18F-DCFPyL PET/CT in Oncocytoma.
Prostatic Neoplasms
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
Prostatic Neoplasms
18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.
Prostatic Neoplasms
18F-rhPSMA-7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy.
Prostatic Neoplasms
1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
Prostatic Neoplasms
225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience.
Prostatic Neoplasms
225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient.
Prostatic Neoplasms
3D-printed supercapacitor-powered electrochemiluminescent protein immunoarray.
Prostatic Neoplasms
64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer.
Prostatic Neoplasms
68 Ga-prostate-specific membrane antigen tracers can alter the management of more than half of prostate cancer patients with biochemical recurrence.
Prostatic Neoplasms
68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
Prostatic Neoplasms
68 Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.
Prostatic Neoplasms
68-gallium Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Detects Rare Testicular Metastasis from Prostate Cancer.
Prostatic Neoplasms
68Ga Prostate-specific Membrane Antigen PET/CT for Primary Diagnosis of Prostate Cancer: Complementary or Alternative to Multiparametric MR Imaging.
Prostatic Neoplasms
68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
Prostatic Neoplasms
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Prostatic Neoplasms
68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.
Prostatic Neoplasms
68Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent.
Prostatic Neoplasms
68Ga-Labeled PSMA Uptake in Nonprostatic Malignancies: Has the Time Come to Remove "PS" From PSMA?
Prostatic Neoplasms
68Ga-Prostate-Specific Membrane Antigen 11 PET/CT Detects Residual Glioblastoma After Radical Surgery in a Patient With Synchronous Recurrent Prostate Cancer: A Case Report.
Prostatic Neoplasms
68Ga-Prostate-Specific Membrane Antigen PET/CT in Triple-Negative Breast Cancer.
Prostatic Neoplasms
68Ga-Prostate-Specific Membrane Antigen PET/CT Uptake in Intraventricular Meningioma in the Choroid Plexus.
Prostatic Neoplasms
68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
Prostatic Neoplasms
68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.
Prostatic Neoplasms
68Ga-Prostate-Specific Membrane Antigen-Avid Tubercular Lesions Mimicking Prostate Cancer Metastasis on Simultaneous Prostate-Specific Membrane Antigen PET/MRI.
Prostatic Neoplasms
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer.
Prostatic Neoplasms
68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients.
Prostatic Neoplasms
68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy.
Prostatic Neoplasms
68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future?
Prostatic Neoplasms
68Ga-PSMA PET/CT Imaging and 153Sm-EDTMP Bone Pain Palliation Therapy.
Prostatic Neoplasms
68Ga-PSMA PET/CT Imaging in Multiple Myeloma.
Prostatic Neoplasms
68Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?
Prostatic Neoplasms
68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer.
Prostatic Neoplasms
68Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: A meta-analysis.
Prostatic Neoplasms
68Ga-PSMA Uptake in Middle Lobe Syndrome.
Prostatic Neoplasms
68Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership.
Prostatic Neoplasms
68Ga-PSMA-11 PET imaging in patients with ongoing androgen deprivation therapy for advanced prostate cancer.
Prostatic Neoplasms
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.
Prostatic Neoplasms
68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability.
Prostatic Neoplasms
68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
Prostatic Neoplasms
68Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients' disease management and adequacy of impact.
Prostatic Neoplasms
68Ga-PSMA-11 PET/MR Can Be False Positive in Normal Prostatic Tissue.
Prostatic Neoplasms
68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study.
Prostatic Neoplasms
68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer.
Prostatic Neoplasms
68Ga-PSMA-I&T-PET/CT interobserver and intraobserver agreement for prostate cancer: a lesion based and subregional comparison study among observers with different levels of experience.
Prostatic Neoplasms
68Ga-PSMA-Ligand PET/CT Uptake in Anthracosilicosis.
Prostatic Neoplasms
68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial.
Prostatic Neoplasms
68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.
Prostatic Neoplasms
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer.
Prostatic Neoplasms
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Prostatic Neoplasms
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
Prostatic Neoplasms
99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions.
Prostatic Neoplasms
99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.
Prostatic Neoplasms
??Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
Prostatic Neoplasms
?Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma.
Prostatic Neoplasms
A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen.
Prostatic Neoplasms
A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Prostatic Neoplasms
A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention.
Prostatic Neoplasms
A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA-11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models.
Prostatic Neoplasms
A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion.
Prostatic Neoplasms
A Comprehensive Safety Evaluation of 68Ga-Labeled Ligand Prostate-Specific Membrane Antigen 11 PET/CT in Prostate Cancer: The Results of 2 Prospective, Multicenter Trials.
Prostatic Neoplasms
A designer bow-tie combination therapeutic platform: An approach to resistant cancer treatment by simultaneous delivery of cytotoxic and anti-inflammatory agents and radiation.
Prostatic Neoplasms
A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.
Prostatic Neoplasms
A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.
Prostatic Neoplasms
A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Prostatic Neoplasms
A Highly Specific Multiple Enhancement Theranostic Nanoprobe for PET/MRI/PAI Image-Guided Radioisotope Combined Photothermal Therapy in Prostate Cancer.
Prostatic Neoplasms
A Low Molecular Weight PSMA-Based Fluorescent Imaging Agent for Cancer.
Prostatic Neoplasms
A microdose clinical trial to evaluate [18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer.
Prostatic Neoplasms
A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA).
Prostatic Neoplasms
A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Prostatic Neoplasms
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen.
Prostatic Neoplasms
A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging.
Prostatic Neoplasms
A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
Prostatic Neoplasms
A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Prostatic Neoplasms
A pharmacoeconomic evaluation of staging modalities for patients with newly diagnosed and occult recurrent adenocarcinoma of the prostate.
Prostatic Neoplasms
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY).
Prostatic Neoplasms
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.
Prostatic Neoplasms
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
Prostatic Neoplasms
A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma.
Prostatic Neoplasms
A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent.
Prostatic Neoplasms
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
Prostatic Neoplasms
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Prostatic Neoplasms
A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.
Prostatic Neoplasms
A Prospective Study on [68Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
Prostatic Neoplasms
A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile.
Prostatic Neoplasms
A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
Prostatic Neoplasms
A PSMA-targeted theranostic agent for photodynamic therapy.
Prostatic Neoplasms
A Rare Case of Omentum Invasive Prostate Cancer: Staging With PSMA PET/CT Imaging and Response to Systemic Therapy.
Prostatic Neoplasms
A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.
Prostatic Neoplasms
A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.
Prostatic Neoplasms
A Retrospective Analysis of the Safety and Activity of Lutetium-177-PSMA Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
Prostatic Neoplasms
A ribonucleoprotein octamer for targeted siRNA delivery.
Prostatic Neoplasms
A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Prostatic Neoplasms
A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer.
Prostatic Neoplasms
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals.
Prostatic Neoplasms
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.
Prostatic Neoplasms
A Structure-Activity Relationship Study of Bimodal BODIPY-Labeled PSMA-Targeting Bioconjugates.
Prostatic Neoplasms
A targeted low molecular weight near-infrared fluorescent probe for prostate cancer.
Prostatic Neoplasms
A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy?
Prostatic Neoplasms
Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes.
Prostatic Neoplasms
Active Giant Cell Vasculitis Diagnosis with 68Ga PSMA PET/CT Imaging.
Prostatic Neoplasms
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Prostatic Neoplasms
Adding prostate-specific membrane antigen positron emission tomography (PSMA PET) to our prostate cancer armamentarium raises many questions.
Prostatic Neoplasms
Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
Prostatic Neoplasms
Advancement of MR and PET/MR in Prostate Cancer.
Prostatic Neoplasms
Advances in positron emission tomography applications for urologic cancers.
Prostatic Neoplasms
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Prostatic Neoplasms
Advances in prostate cancer.
Prostatic Neoplasms
Advances in prostate-specific membrane antigen PET of prostate cancer.
Prostatic Neoplasms
Advances in PSMA-targeted therapy for prostate cancer.
Prostatic Neoplasms
Advances in Targeted Alpha Therapy for Prostate Cancer.
Prostatic Neoplasms
Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.
Prostatic Neoplasms
Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Prostatic Neoplasms
Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617.
Prostatic Neoplasms
Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy.
Prostatic Neoplasms
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.
Prostatic Neoplasms
Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding.
Prostatic Neoplasms
Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells.
Prostatic Neoplasms
An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells.
Prostatic Neoplasms
An Impressive Approach in Nuclear Medicine: Theranostics.
Prostatic Neoplasms
An improved 211At-labeled agent for PSMA-targeted alpha therapy.
Prostatic Neoplasms
An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligands.
Prostatic Neoplasms
An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay.
Prostatic Neoplasms
An ultrasound-responsive dual-modal US/T1 -MRI contrast agent for potential diagnosis of prostate cancer.
Prostatic Neoplasms
Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients.
Prostatic Neoplasms
Analysis of prostate-specific membrane antigen splice variants in LNCap cells.
Prostatic Neoplasms
Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer.
Prostatic Neoplasms
Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
Prostatic Neoplasms
Anti-PSMA monoclonal antibody increases the toxicity of paclitaxel carried by carbon nanotubes.
Prostatic Neoplasms
Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation.
Prostatic Neoplasms
Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics.
Prostatic Neoplasms
Antibody-drug conjugates targeting prostate-specific membrane antigen.
Prostatic Neoplasms
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
Prostatic Neoplasms
Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study.
Prostatic Neoplasms
Application of Cu-64 NODAGA-PSMA PET in Prostate Cancer.
Prostatic Neoplasms
Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.
Prostatic Neoplasms
Aptamers and apple pies: a mini-review of PSMA aptamers and lessons from Donald S. Coffey.
Prostatic Neoplasms
Assessing Response to [177Lu]PSMA Radioligand Therapy using modified PSMA PET Progression Criteria.
Prostatic Neoplasms
Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
Prostatic Neoplasms
Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction.
Prostatic Neoplasms
Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Prostatic Neoplasms
Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
Prostatic Neoplasms
Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience.
Prostatic Neoplasms
Association of glutamate carboxypeptidase II (GCPII) haplotypes with breast and prostate cancer risk.
Prostatic Neoplasms
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Prostatic Neoplasms
Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer.
Prostatic Neoplasms
Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.
Prostatic Neoplasms
Automated radiosynthesis of [68 Ga]Ga-PSMA-11 and [177 Lu]Lu-PSMA-617 on the iPHASE MultiSyn module for clinical applications.
Prostatic Neoplasms
Automated synthesis module and sterile cold kit for 68Ga-PSMA-11 do not show differences in PET/CT image quality.
Prostatic Neoplasms
Automated synthesis of 68 Ga/177 Lu-PSMA on the Trasis miniAllinOne.
Prostatic Neoplasms
Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models.
Prostatic Neoplasms
Automated synthesis of [18F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions.
Prostatic Neoplasms
Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination.
Prostatic Neoplasms
Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer.
Prostatic Neoplasms
Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation.
Prostatic Neoplasms
Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells.
Prostatic Neoplasms
Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging.
Prostatic Neoplasms
Biochemical Recurrence of Prostate Cancer Presenting as Solitary Testicular Metastasis on 68Ga-Labeled Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography.
Prostatic Neoplasms
Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells.
Prostatic Neoplasms
Bioconjugated Gold Nanoparticles Enhance siRNA Delivery in Prostate Cancer Cells.
Prostatic Neoplasms
Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges.
Prostatic Neoplasms
Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.
Prostatic Neoplasms
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.
Prostatic Neoplasms
Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
Prostatic Neoplasms
Biomarkers in Prostate-Specific Membrane Antigen Theranostics.
Prostatic Neoplasms
Biorecognition and Subcellular Trafficking of HPMA Copolymer-Anti-PSMA Antibody Conjugates by Prostate Cancer Cells.
Prostatic Neoplasms
Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.
Prostatic Neoplasms
Bispecific radioligands targeting prostate-specific membrane antigen and gastrin-releasing peptide receptors on the surface of prostate cancer cells.
Prostatic Neoplasms
Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer.
Prostatic Neoplasms
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
Prostatic Neoplasms
Bone-Targeted Drug Delivery Systems and Strategies for Treatment of Bone Metastasis.
Prostatic Neoplasms
Bridging the imaging gap: PSMA PET/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence - a narrative review of literature.
Prostatic Neoplasms
Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer.
Prostatic Neoplasms
Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.
Prostatic Neoplasms
Camel heavy chain antibodies against prostate-specific membrane antigen.
Prostatic Neoplasms
Can 68Ga-PSMA-11 PET/CT predict pathological upgrading of prostate cancer from MRI-targeted biopsy to radical prostatectomy?
Prostatic Neoplasms
Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?
Prostatic Neoplasms
Can Gallium-68 Prostate-specific Membrane Antigen Ligand be a Potential Radiotracer for Renal Cortical Positron Emission Tomography Imaging?
Prostatic Neoplasms
Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Prostatic Neoplasms
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
Prostatic Neoplasms
Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer.
Prostatic Neoplasms
Cancer immunotherapy for prostate cancer.
Prostatic Neoplasms
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.
Prostatic Neoplasms
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.
Prostatic Neoplasms
Cartography-based quality control of prostate cancer care: a necessary ground to targeted focal therapy.
Prostatic Neoplasms
Cell Membrane-Inspired Polymeric Vesicles for Combined Photothermal and Photodynamic Prostate Cancer Therapy.
Prostatic Neoplasms
Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer.
Prostatic Neoplasms
Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer.
Prostatic Neoplasms
Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
Prostatic Neoplasms
Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen.
Prostatic Neoplasms
Cerebellar Metastases From Prostate Cancer on 68Ga-PSMA PET/CT.
Prostatic Neoplasms
Changes in gene expression and targets for therapy.
Prostatic Neoplasms
Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
Prostatic Neoplasms
Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture.
Prostatic Neoplasms
Characterization of prostate cancer cell progression in zebrafish xenograft model.
Prostatic Neoplasms
Characterization of the enzymatic activity of PSM: comparison with brain NAALADase.
Prostatic Neoplasms
Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer.
Prostatic Neoplasms
Chemically synthesized molecules with the targeting and effector functions of antibodies.
Prostatic Neoplasms
Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads.
Prostatic Neoplasms
Chemoprevention of Bladder and Prostate Carcinoma.
Prostatic Neoplasms
Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation.
Prostatic Neoplasms
Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer.
Prostatic Neoplasms
Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction.
Prostatic Neoplasms
Clinical Impact of Lower-Limb Imaging in 68Ga-PSMA PET/CT for Patients with Prostate Cancer.
Prostatic Neoplasms
Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
Prostatic Neoplasms
Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities.
Prostatic Neoplasms
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy.
Prostatic Neoplasms
Clinical outcomes of 177Lu-PSMA radioligand therapy in taxane chemotherapy pretreated and taxane chemotherapy naïve patients with metastatic castration resistant prostate cancer.
Prostatic Neoplasms
Clinical parameters and nomograms for predicting lymph node metastasis detected with 68 Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
Prostatic Neoplasms
Clinical PET/MR.
Prostatic Neoplasms
Clinical translation of a PSMA inhibitor for (99m)Tc-based SPECT.
Prostatic Neoplasms
Clinical Translation of Positive Metastases Identified on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging in the Management of De Novo Synchronous Oligometastatic Prostate Cancer.
Prostatic Neoplasms
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.
Prostatic Neoplasms
Clinical trials of cancer therapies targeting prostate-specific membrane antigen.
Prostatic Neoplasms
Clinical utility of genetic variants of glutamate carboxypeptidase II in predicting breast cancer and prostate cancer risk.
Prostatic Neoplasms
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
Prostatic Neoplasms
Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
Prostatic Neoplasms
Cloning and characterization of canine prostate-specific membrane antigen.
Prostatic Neoplasms
Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase.
Prostatic Neoplasms
Combination of Forced Diuresis with Additional Late Imaging in 68Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake.
Prostatic Neoplasms
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Prostatic Neoplasms
Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy.
Prostatic Neoplasms
Combined Application of Albumin-Binding [177Lu]Lu-PSMA-ALB-56 and Fast-Cleared PSMA Inhibitors: Optimization of the Pharmacokinetics.
Prostatic Neoplasms
Combined Intravenous Urogram and 68Ga-PSMA PET/ CT for Improved Staging and Restaging of Prostate Cancer.
Prostatic Neoplasms
Combined model-based and patient-specific dosimetry for
Prostatic Neoplasms
Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.
Prostatic Neoplasms
Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage.
Prostatic Neoplasms
Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology.
Prostatic Neoplasms
Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.
Prostatic Neoplasms
Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
Prostatic Neoplasms
Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer.
Prostatic Neoplasms
Comparison of planar, PET and well-counter measurements of total tumor radioactivity in a mouse xenograft model.
Prostatic Neoplasms
Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy.
Prostatic Neoplasms
Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Prostatic Neoplasms
Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.
Prostatic Neoplasms
Comparison of Prostate-Specific Membrane Antigen Expression Levels in Human Salivary Glands to Non-Human Primates and Rodents.
Prostatic Neoplasms
Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer.
Prostatic Neoplasms
Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.
Prostatic Neoplasms
Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma.
Prostatic Neoplasms
Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
Prostatic Neoplasms
Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.
Prostatic Neoplasms
Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality.
Prostatic Neoplasms
Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples.
Prostatic Neoplasms
Comparison of three interpretation criteria of 68Ga-PSMA11 PET based on inter- and intra-reader agreement.
Prostatic Neoplasms
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Prostatic Neoplasms
Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Prostatic Neoplasms
Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of 177 Lu-PSMA-617 in LNCaP cells.
Prostatic Neoplasms
Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Prostatic Neoplasms
Conformational and SAR analysis of NAALADase and PSMA inhibitors.
Prostatic Neoplasms
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer.
Prostatic Neoplasms
Constitutive and antibody-induced internalization of prostate-specific membrane antigen.
Prostatic Neoplasms
Construction and in vitro/in vivo targeting of PSMA-targeted nanoscale microbubbles in prostate cancer.
Prostatic Neoplasms
Convenient Preparation of [(68)Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy.
Prostatic Neoplasms
Correction to: Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells.
Prostatic Neoplasms
Correction: Identification and Characterization of Nuclease-Stabilized RNA Molecules That Bind Human Prostate Cancer Cells via the Prostate-Specific Membrane Antigen.
Prostatic Neoplasms
Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer.
Prostatic Neoplasms
Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis.
Prostatic Neoplasms
Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.
Prostatic Neoplasms
Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer.
Prostatic Neoplasms
Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.
Prostatic Neoplasms
Correlations of 68Ga-PSMA PET/CT in the initial staging of prostate cancer patients.
Prostatic Neoplasms
Correlations of the 68Ga-PSMA PET/CT derived primary prostate tumor PSMA expression parameters and metastatic patterns in patients with Gleason Score >7 prostate cancer.
Prostatic Neoplasms
Correspondence re: Ghosh A and Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539, 2004.
Prostatic Neoplasms
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.
Prostatic Neoplasms
Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer.
Prostatic Neoplasms
Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer.
Prostatic Neoplasms
Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Prostatic Neoplasms
Current status of PSMA PET imaging in prostate cancer.
Prostatic Neoplasms
Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov.
Prostatic Neoplasms
Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.
Prostatic Neoplasms
Current status of theranostics in prostate cancer.
Prostatic Neoplasms
Current use of PSMA-PET in prostate cancer management.
Prostatic Neoplasms
Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies.
Prostatic Neoplasms
Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models.
Prostatic Neoplasms
Day-to-day variability of [68Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation.
Prostatic Neoplasms
Dedicated Verification of an Accessory Parotid Gland via Minimal-Activity PSMA-PET/CT.
Prostatic Neoplasms
Dendritic cell-based immunotherapy of prostate cancer.
Prostatic Neoplasms
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
Prostatic Neoplasms
Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis.
Prostatic Neoplasms
Design and synthesis of a novel BODIPY-labeled PSMA inhibitor.
Prostatic Neoplasms
Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.
Prostatic Neoplasms
Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II.
Prostatic Neoplasms
Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Prostatic Neoplasms
Design, synthesis and pharmacological activity of novel enantiomerically pure phosphonic acid-based NAALADase inhibitors.
Prostatic Neoplasms
Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens.
Prostatic Neoplasms
Detection and quantitation of glutamate carboxypeptidase II in human blood.
Prostatic Neoplasms
Detection efficacy of 18F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
Prostatic Neoplasms
Detection efficacy of [18F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy.
Prostatic Neoplasms
Detection of a Meckel's diverticulum on PSMA PET/CT: A case report.
Prostatic Neoplasms
Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade.
Prostatic Neoplasms
Detection of hematogenous dissemination of prostatic cancer by RT-PCR with primers specific for prostate-specific membrane antigen.
Prostatic Neoplasms
Detection of Local Relapse of Prostate Cancer With 18F-PSMA-1007.
Prostatic Neoplasms
Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
Prostatic Neoplasms
Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
Prostatic Neoplasms
Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium.
Prostatic Neoplasms
Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy.
Prostatic Neoplasms
Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis.
Prostatic Neoplasms
Detection Rate of 68Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy.
Prostatic Neoplasms
Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
Prostatic Neoplasms
Detection rates of recurrent prostate cancer: 68Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET/CT scans. A systematic review.
Prostatic Neoplasms
Development and Screening of a Series of Antibody-Conjugated and Silica-Coated Iron Oxide Nanoparticles for Targeting the Prostate-Specific Membrane Antigen.
Prostatic Neoplasms
Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer.
Prostatic Neoplasms
Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.
Prostatic Neoplasms
Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen.
Prostatic Neoplasms
Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution.
Prostatic Neoplasms
Development of a High-Throughput Fluorescence Polarization Assay to Identify Novel Ligands of Glutamate Carboxypeptidase II.
Prostatic Neoplasms
Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Prostatic Neoplasms
Development of a Single Stranded DNA Aptamer as a Molecular Probe for LNCap Cells Using Cell-SELEX.
Prostatic Neoplasms
Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients.
Prostatic Neoplasms
Development of an Albumin-Based PSMA Probe With Prolonged Half-Life.
Prostatic Neoplasms
Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [177Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome.
Prostatic Neoplasms
Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition.
Prostatic Neoplasms
Development of polymeric microbubbles targeted to prostate-specific membrane antigen as prototype of novel ultrasound contrast agents.
Prostatic Neoplasms
Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors.
Prostatic Neoplasms
Development of targeted near-infrared imaging agents for prostate cancer.
Prostatic Neoplasms
Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Prostatic Neoplasms
Diagnostic Accuracy of (64)Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.
Prostatic Neoplasms
Diagnostic accuracy of 18F-PSMA-1007-PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence.
Prostatic Neoplasms
Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI.
Prostatic Neoplasms
Diagnostic accuracy of 68 Ga-PSMA PET/MRI and multiparametric MRI in detecting index tumours in radical prostatectomy specimen.
Prostatic Neoplasms
Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer.
Prostatic Neoplasms
Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Prostatic Neoplasms
Diagnostic Accuracy of Multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer.
Prostatic Neoplasms
Diagnostic performance of
Prostatic Neoplasms
Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer.
Prostatic Neoplasms
Diagnostic Performance of 68Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer.
Prostatic Neoplasms
Diagnostic Performance of ??Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis.
Prostatic Neoplasms
Diagnostic performance of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography in intermediate and high risk prostate cancer.
Prostatic Neoplasms
Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
Prostatic Neoplasms
Diagnostic Performance of [18F]Fluorocholine and [68Ga]Ga-PSMA PET/CT in Prostate Cancer: A Comparative Study.
Prostatic Neoplasms
Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review.
Prostatic Neoplasms
Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging.
Prostatic Neoplasms
Differences in the expression of telomerase and prostate-specific membrane antigen in non-advanced prostatic cancer.
Prostatic Neoplasms
Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for FDG imaging of PSMA-suppressed tumors.
Prostatic Neoplasms
Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients.
Prostatic Neoplasms
Differing effects of microtubule depolymerizing and stabilizing chemotherapeutic agents on t-SNARE-mediated apical targeting of prostate-specific membrane antigen.
Prostatic Neoplasms
Dipeptide inhibitors of the prostate specific membrane antigen (PSMA): A comparison of urea and thiourea derivatives.
Prostatic Neoplasms
Discovery of 18F-JK-PSMA-7, a novel PET-probe for the detection of small PSMA positive lesions.
Prostatic Neoplasms
Discovery of PSMA-specific peptide ligands for targeted drug delivery.
Prostatic Neoplasms
Discrepancy between Multiparametric Magnetic Resonance Imaging and 68Ga Prostate-Specific Membrane Antigen Positron Emission Tomography: A Simultaneous Acquired Positron Emission Tomography-Magnetic Resonance Imaging Case.
Prostatic Neoplasms
Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen.
Prostatic Neoplasms
DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer.
Prostatic Neoplasms
Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Prostatic Neoplasms
Does lymph node localization affect prostate-specific membrane antigen uptake?
Prostatic Neoplasms
Dual contrast agents for fluorescence and photoacoustic imaging: evaluation in a murine model of prostate cancer.
Prostatic Neoplasms
Dual-labeled prostate-specific membrane antigen (PSMA)-targeting agent for preoperative molecular imaging and fluorescence-guided surgery for prostate cancer.
Prostatic Neoplasms
Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
Prostatic Neoplasms
Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
Prostatic Neoplasms
Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review.
Prostatic Neoplasms
DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selective prostate cancer cell targeting.
Prostatic Neoplasms
Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions.
Prostatic Neoplasms
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).
Prostatic Neoplasms
Early dynamic imaging in (68)Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.
Prostatic Neoplasms
Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer.
Prostatic Neoplasms
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Prostatic Neoplasms
Early prostate cancer recurrence with prostate-specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579).
Prostatic Neoplasms
Editorial Comment to Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?
Prostatic Neoplasms
Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen.
Prostatic Neoplasms
Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
Prostatic Neoplasms
Effect of external cooling on Lu-177 PSMA uptake for parotid glands.
Prostatic Neoplasms
Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer.
Prostatic Neoplasms
Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists.
Prostatic Neoplasms
Effective targeting of prostate cancer by lymphocytes redirected by a PSMA?×?CD3 bispecific single-chain diabody.
Prostatic Neoplasms
Effects of 225Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: A meta-analysis.
Prostatic Neoplasms
Effects of Linker Modification on Tumor-to-Kidney Contrast of 68Ga-Labeled PSMA-Targeted Imaging Probes.
Prostatic Neoplasms
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-? Insensitive Genetically Targeted CD8
Prostatic Neoplasms
Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients.
Prostatic Neoplasms
Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study.
Prostatic Neoplasms
Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia - A prospective study.
Prostatic Neoplasms
Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
Prostatic Neoplasms
Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer.
Prostatic Neoplasms
Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond.
Prostatic Neoplasms
Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches.
Prostatic Neoplasms
Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization.
Prostatic Neoplasms
Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor
Prostatic Neoplasms
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.
Prostatic Neoplasms
Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization.
Prostatic Neoplasms
Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
Prostatic Neoplasms
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Prostatic Neoplasms
Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
Prostatic Neoplasms
Enzymatic radiosynthesis of a 18F-Glu-Ureido-Lys ligand for the prostate-specific membrane antigen (PSMA).
Prostatic Neoplasms
Erratum: Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: Systematic Review and Network Meta-Analysis.
Prostatic Neoplasms
Establishing (177)Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer.
Prostatic Neoplasms
Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada.
Prostatic Neoplasms
Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET/CT: a real-world study.
Prostatic Neoplasms
EV-Ident: Identifying Tumor-Specific Extracellular Vesicles by Size Fractionation and Single-Vesicle Analysis.
Prostatic Neoplasms
Evaluating a Machine Learning Tool for the Classification of Pathological Uptake in Whole-Body PSMA-PET-CT Scans.
Prostatic Neoplasms
Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
Prostatic Neoplasms
Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis.
Prostatic Neoplasms
Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
Prostatic Neoplasms
Evaluation of Hybrid ??Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.
Prostatic Neoplasms
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides.
Prostatic Neoplasms
Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs.
Prostatic Neoplasms
Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
Prostatic Neoplasms
Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
Prostatic Neoplasms
Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
Prostatic Neoplasms
Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer.
Prostatic Neoplasms
Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer.
Prostatic Neoplasms
Evaluation of the PSMA-Binding Ligand 212Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer.
Prostatic Neoplasms
Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Prostatic Neoplasms
Evolution of Peptide-Based Prostate-Specific Membrane Antigen (PSMA) Inhibitors: An Approach to Novel Prostate Cancer Therapeutics.
Prostatic Neoplasms
Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis.
Prostatic Neoplasms
Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
Prostatic Neoplasms
Exciting Opportunities in Nuclear Medicine Imaging and Therapy.
Prostatic Neoplasms
Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.
Prostatic Neoplasms
Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen.
Prostatic Neoplasms
Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer.
Prostatic Neoplasms
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
Prostatic Neoplasms
Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3.
Prostatic Neoplasms
Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.
Prostatic Neoplasms
Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid.
Prostatic Neoplasms
Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.
Prostatic Neoplasms
Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma.
Prostatic Neoplasms
Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
Prostatic Neoplasms
Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Prostatic Neoplasms
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Prostatic Neoplasms
External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.
Prostatic Neoplasms
Extrapleural solitary fibrous tumor evidenced by 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography study in the staging of a high-risk prostate cancer patient.
Prostatic Neoplasms
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
Prostatic Neoplasms
Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received 177Lu PSMA I&T therapy.
Prostatic Neoplasms
False-positive prostate cancer bone metastases on magnetic resonance imaging correctly classified on gallium-68-prostate-specific membrane antigen positron emission tomography computed tomography.
Prostatic Neoplasms
Fibrous dysplasia as a possible false-positive finding in 68Ga-labeled prostate-specific membrane antigen positron emission tomography/computed tomography study in the follow-up of prostate cancer.
Prostatic Neoplasms
Fine-tuning of the automated [18 F]PSMA-1007 radiosynthesis.
Prostatic Neoplasms
First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer.
Prostatic Neoplasms
First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer.
Prostatic Neoplasms
First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer.
Prostatic Neoplasms
Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Prostatic Neoplasms
Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.
Prostatic Neoplasms
Flow cytometric detection of prostate tumor cells using chemoaffinity labels.
Prostatic Neoplasms
Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls.
Prostatic Neoplasms
Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
Prostatic Neoplasms
Fluorodeoxyglucose, sodium fluoride, and prostate-specific membrane antigen positron emission tomography studies for treatment response assessment in prostate cancer.
Prostatic Neoplasms
Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature.
Prostatic Neoplasms
Folic acid on iron oxide nanoparticles: platform with high potential for simultaneous targeting, MRI detection and hyperthermia treatment of lymph node metastases of prostate cancer.
Prostatic Neoplasms
Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT.
Prostatic Neoplasms
Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides.
Prostatic Neoplasms
Follow-Up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Prostatic Neoplasms
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
Prostatic Neoplasms
Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery.
Prostatic Neoplasms
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
Prostatic Neoplasms
Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells.
Prostatic Neoplasms
Functionalized NIR-II Semiconducting Polymer Nanoparticles for Single-cell to Whole-Organ Imaging of PSMA-Positive Prostate Cancer.
Prostatic Neoplasms
Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Prostatic Neoplasms
Gallium-68 prostate-specific membrane antigen PET-CT and the clinical management of prostate cancer.
Prostatic Neoplasms
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Prostatic Neoplasms
Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer.
Prostatic Neoplasms
Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography for staging of high-risk prostate cancer.
Prostatic Neoplasms
Gallium-68 PSMA uptake in adrenal adenoma.
Prostatic Neoplasms
Gastric GIST Incidentally Detected on 68Ga-PSMA-PET/CT: Correlation Between Functional Imaging and Histology.
Prostatic Neoplasms
Gastric Metastasis of Prostate Cancer as an Unusual Presentation Using 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Prostatic Neoplasms
Gastrin-Releasing Peptide Receptor in Low Grade Prostate Cancer: Can It Be a Better Predictor Than Prostate-Specific Membrane Antigen?
Prostatic Neoplasms
GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD.
Prostatic Neoplasms
GCPII Variants, Paralogs and Orthologs.
Prostatic Neoplasms
Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
Prostatic Neoplasms
Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
Prostatic Neoplasms
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted ?-particle therapy.
Prostatic Neoplasms
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Prostatic Neoplasms
Global experience with PSMA-based alpha therapy in prostate cancer.
Prostatic Neoplasms
Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers.
Prostatic Neoplasms
Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer.
Prostatic Neoplasms
Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
Prostatic Neoplasms
GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial.
Prostatic Neoplasms
Growth and characterization of LNCaP prostate cancer cell spheroids.
Prostatic Neoplasms
Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.
Prostatic Neoplasms
Head- to head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard.
Prostatic Neoplasms
Healing Sacral Fracture Masquerading as Metastatic Bone Disease on a 68Ga-PSMA PET/CT.
Prostatic Neoplasms
Health-Related Quality-of-Life Outcomes with Actinium-225-Prostate-Specific Membrane Antigen-617 Therapy in Patients with Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Hemangioblastoma: An Unsuspected Pitfall in PSMA PET/CT.
Prostatic Neoplasms
Herniated Thoracic Spleen Mimicking Lung Metastasis on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in a Patient With Prostate Cancer.
Prostatic Neoplasms
Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model.
Prostatic Neoplasms
Heterogeneous 68Ga-Prostate-Specific Membrane Antigen Uptake in the Left Upper Abdomen: Mesenchymal Tumor.
Prostatic Neoplasms
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Prostatic Neoplasms
Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer.
Prostatic Neoplasms
High 18Fluor-DCFPyL Uptake in Adrenal Adenomas.
Prostatic Neoplasms
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.
Prostatic Neoplasms
High expression of PSM-E correlated with tumor grade in prostate cancer: A new alternatively spliced variant of prostate-specific membrane antigen.
Prostatic Neoplasms
High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer.
Prostatic Neoplasms
High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA.
Prostatic Neoplasms
High-Throughput Electrochemical Microfluidic Immunoarray for Multiplexed Detection of Cancer Biomarker Proteins.
Prostatic Neoplasms
Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device.
Prostatic Neoplasms
Highly sensitive electrochemiluminescence detection of a prostate cancer biomarker.
Prostatic Neoplasms
Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
Prostatic Neoplasms
Home tests for prostate-specific membrane antigen being developed for prostate cancer diagnosis.
Prostatic Neoplasms
Hong Kong Urological Association-Hong Kong Society of Uro-Oncology consensus statements on the management of advanced prostate cancer-2019 Updates.
Prostatic Neoplasms
How prostate-specific membrane antigen level may be correlated with stemness in prostate cancer stem cell-like cell populations?
Prostatic Neoplasms
Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients.
Prostatic Neoplasms
Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.
Prostatic Neoplasms
Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen - Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction.
Prostatic Neoplasms
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.
Prostatic Neoplasms
Identification of a novel microsatellite marker tightly linked to the KAI-1 gene for predicting prostate cancer progression.
Prostatic Neoplasms
Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
Prostatic Neoplasms
Identification of an antibody fragment specific for androgen-dependent prostate cancer cells.
Prostatic Neoplasms
Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.
Prostatic Neoplasms
Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation.
Prostatic Neoplasms
Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
Prostatic Neoplasms
Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617.
Prostatic Neoplasms
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
Prostatic Neoplasms
Image of the Month: Multifocal 68Ga Prostate-Specific Membrane Antigen Ligand Uptake in the Skeleton in a Man With Both Prostate Cancer and Multiple Myeloma.
Prostatic Neoplasms
Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?
Prostatic Neoplasms
Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.
Prostatic Neoplasms
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted ?-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Imaging for Prostate Cancer Recurrence.
Prostatic Neoplasms
Imaging of Non-Prostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms.
Prostatic Neoplasms
Imaging of Prostate Cancer Using (64)Cu-Labeled Prostate-Specific Membrane Antigen Ligand.
Prostatic Neoplasms
Imaging of Prostate Cancer.
Prostatic Neoplasms
Imaging of prostate cancer: optimizing affinity to prostate specific membrane antigen by spacer modifications in a tumor spheroid model.
Prostatic Neoplasms
Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
Prostatic Neoplasms
Imaging of Prostate-Specific Membrane Antigen Using [(18)F]DCFPyL.
Prostatic Neoplasms
Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications.
Prostatic Neoplasms
Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.
Prostatic Neoplasms
Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer.
Prostatic Neoplasms
Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging.
Prostatic Neoplasms
Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.
Prostatic Neoplasms
Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET.
Prostatic Neoplasms
Immunohistochemical Reactivity of Prostate-Specific Membrane Antigen in Salivary Gland Tumors.
Prostatic Neoplasms
Immunohistochemical validation of PSMA-expression measured by (68)Ga-PSMA PET/CT in primary prostate cancer.
Prostatic Neoplasms
Immunotherapy for prostate cancer.
Prostatic Neoplasms
Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
Prostatic Neoplasms
Impact of 68Ga-PSMA-11 PET on the Management of recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial.
Prostatic Neoplasms
Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single Center Study.
Prostatic Neoplasms
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Impact of short-term Dutasteride treatment on prostate-specific membrane antigen expression in a mouse xenograft model.
Prostatic Neoplasms
Impact of the Noise Penalty Factor on Quantification in Bayesian Penalized Likelihood (Q.Clear) Reconstructions of 68Ga-PSMA PET/CT Scans.
Prostatic Neoplasms
Implications of a new element in the early diagnostic pathway for prostate cancer for rural Australians.
Prostatic Neoplasms
Improved effects of a double suicide gene system on prostate cancer cells by targeted regulation of prostate-specific membrane antigen promoter and enhancer.
Prostatic Neoplasms
Improved oncological outcome after radical prostatectomy in patients staged with 68Ga-PSMA-11 PET: a single-center retrospective cohort comparison.
Prostatic Neoplasms
Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology.
Prostatic Neoplasms
Improving 68-Ga-PSMA PET/MR hybrid imaging of the prostate with un-renormalized absolute scatter correction.
Prostatic Neoplasms
Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker.
Prostatic Neoplasms
In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA.
Prostatic Neoplasms
In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
Prostatic Neoplasms
In vitro and in vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-conjugated Antibody to Prostate-specific Membrane Antigen.
Prostatic Neoplasms
In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Prostatic Neoplasms
In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Prostatic Neoplasms
In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen.
Prostatic Neoplasms
In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles.
Prostatic Neoplasms
In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer--changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile.
Prostatic Neoplasms
In-House Preparation and Quality Control of Ac-225 Prostate-Specific Membrane Antigen-617 for the Targeted Alpha Therapy of Castration-Resistant Prostate Carcinoma.
Prostatic Neoplasms
Incidental 68Ga-Prostate-Specific Membrane Antigen Uptake in Compression Fracture of a Vertebral Body.
Prostatic Neoplasms
Incidental Detection of a Radiation-Induced Soft-Tissue Sarcoma on 68Ga-PSMA PET/CT in a Patient Previously Treated for Prostate Cancer.
Prostatic Neoplasms
Incidental Detection of Hypothyroidism on 68Ga-PSMA-HBED-CC PET/CT Imaging.
Prostatic Neoplasms
Incidental Detection of Pleomorphic Sarcoma on 68Ga-PSMA PET/CT in a Patient With Prostate Cancer.
Prostatic Neoplasms
Incidental detection of primary hepatocellular carcinoma on 18F-prostate-specific membrane antigen-1007 positron emission tomography/computed tomography imaging in a patient with prostate cancer: A case report.
Prostatic Neoplasms
Incidental Detection of Tracer Avidity in Liposarcoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT.
Prostatic Neoplasms
Incidental Detection of Type B2 Thymoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT Imaging.
Prostatic Neoplasms
Incidental finding of ileal gastrointestinal stromal tumour during prostate cancer staging with prostate-specific membrane antigen scan.
Prostatic Neoplasms
Incidental Malignancies identified during staging for Prostate Cancer with (68)Ga -PSMA HBED-CC PET imaging.
Prostatic Neoplasms
Incidental Metastatic Melanoma Identified on 68Ga-Prostate-Specific Membrane Antigen PET/CT for Metastatic Prostate Cancer.
Prostatic Neoplasms
Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective.
Prostatic Neoplasms
Increased PSMA Expression in Castration-Resistant Prostate Cancer Metastases 3 Months After Initiation of Enzalutamide Indicated by 18F-DCFPyL PET/CT.
Prostatic Neoplasms
Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
Prostatic Neoplasms
Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector.
Prostatic Neoplasms
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.
Prostatic Neoplasms
Inflammatory bowel disease and prostate cancer risk: A systematic review.
Prostatic Neoplasms
Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.
Prostatic Neoplasms
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.
Prostatic Neoplasms
Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA.
Prostatic Neoplasms
Inhibitor-GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles.
Prostatic Neoplasms
Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature.
Prostatic Neoplasms
Initial evaluation of PET/CT with 18 F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients.
Prostatic Neoplasms
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Prostatic Neoplasms
Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
Prostatic Neoplasms
Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients.
Prostatic Neoplasms
Initial multicentre experience of (68) gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.
Prostatic Neoplasms
Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
Prostatic Neoplasms
Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer.
Prostatic Neoplasms
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2.
Prostatic Neoplasms
Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.
Prostatic Neoplasms
Interobserver agreement of [68Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer.
Prostatic Neoplasms
Intraobserver and interobserver agreement for the interpretation of 68Ga-prostate-specific membrane antigen-I&T positron emission tomography/computed tomography imaging.
Prostatic Neoplasms
Introduction of Novel Structured Reporting Systems for PET Radiotracers with Potential Theranostic Applications.
Prostatic Neoplasms
Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI.
Prostatic Neoplasms
Is 177Lu-PSMA an effective treatment modality for mCRPC patients with bone and visceral metastasis?
Prostatic Neoplasms
Is prostate-specific membrane antigen a multifunctional protein?
Prostatic Neoplasms
Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
Prostatic Neoplasms
Isolated aplasia of submandibular salivary gland and contralateral prominence of submandibular and sublingual salivary glands incidentally found on 68Ga-prostate-specific membrane antigen positron emission tomography-computed tomography.
Prostatic Neoplasms
Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen.
Prostatic Neoplasms
Juvenile Nasal Angiofibroma on 68Ga-PSMA PET/CT: Opening New Frontiers.
Prostatic Neoplasms
Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents.
Prostatic Neoplasms
Kidney doses in 177Lu-based radioligand therapy in prostate cancer: Is dose estimation based on reduced dosimetry measurements feasible?
Prostatic Neoplasms
Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients.
Prostatic Neoplasms
Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy.
Prostatic Neoplasms
Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer.
Prostatic Neoplasms
Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells.
Prostatic Neoplasms
Lesion Detection and Interobserver Agreement with Advanced Image-Reconstructions for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer.
Prostatic Neoplasms
Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues.
Prostatic Neoplasms
Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors.
Prostatic Neoplasms
Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence.
Prostatic Neoplasms
Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy.
Prostatic Neoplasms
Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.
Prostatic Neoplasms
Long-Circulating Prostate-Specific Membrane Antigen-Targeted NIR Phototheranostic Agent.
Prostatic Neoplasms
Long-range two-photon scattering spectroscopy ruler for screening prostate cancer cells.
Prostatic Neoplasms
Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.
Prostatic Neoplasms
Love Wave Sensor for Prostate-Specific Membrane Antigen Detection Based on Hydrophilic Molecularly-Imprinted Polymer.
Prostatic Neoplasms
Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging.
Prostatic Neoplasms
Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry.
Prostatic Neoplasms
Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.
Prostatic Neoplasms
Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.
Prostatic Neoplasms
Lutetium-177 PSMA Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Prostatic Neoplasms
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Lymph Node Assessment in Prostate Cancer: Evaluation of Iodine Quantification With Spectral Detector CT in Correlation to PSMA PET/CT.
Prostatic Neoplasms
Lymphangitic Carcinomatosis From Prostate Cancer Identified With Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography Imaging.
Prostatic Neoplasms
Machine Learning Facilitates Hotspot Classification in PSMA-PET/CT with Nuclear Medicine Specialist Accuracy.
Prostatic Neoplasms
Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer.
Prostatic Neoplasms
Magnetic polymeric nanobubbles with optimized core size for MRI/ultrasound bimodal molecular imaging of prostate cancer.
Prostatic Neoplasms
Management of positive lymph nodes following radical prostatectomy.
Prostatic Neoplasms
Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis.
Prostatic Neoplasms
Marked Response to 177Lu Prostate-Specific Membrane Antigen Treatment in Patient With Metastatic Prostate Cancer.
Prostatic Neoplasms
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
Prostatic Neoplasms
Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity.
Prostatic Neoplasms
Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
Prostatic Neoplasms
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.
Prostatic Neoplasms
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
Prostatic Neoplasms
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
Prostatic Neoplasms
Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy-Do Different Software Solutions Deliver Comparable Results?
Prostatic Neoplasms
Metal-Based PSMA Radioligands.
Prostatic Neoplasms
Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy.
Prostatic Neoplasms
Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness.
Prostatic Neoplasms
Metastasized 18F-DCFPyL-Negative Prostatic Adenocarcinoma Without Neuroendocrine Differentiation.
Prostatic Neoplasms
Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or
.
Prostatic Neoplasms
Methylation state of the prostate specific membrane antigen (PSMA) CpG island in prostate cancer cell lines.
Prostatic Neoplasms
Microfluidic-integrated patterned ITO immunosensor for rapid detection of prostate-specific membrane antigen biomarker in prostate cancer.
Prostatic Neoplasms
Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer.
Prostatic Neoplasms
Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis.
Prostatic Neoplasms
Modular Synthesis of DOTA-Metal-Based PSMA-Targeted Imaging Agents for MRI and PET of Prostate Cancer.
Prostatic Neoplasms
Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer.
Prostatic Neoplasms
Molecular determination of surgical margins using fossa biopsies at radical prostatectomy.
Prostatic Neoplasms
Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA.
Prostatic Neoplasms
Molecular Imaging of Prostate Cancer.
Prostatic Neoplasms
Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer.
Prostatic Neoplasms
Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
Prostatic Neoplasms
Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer.
Prostatic Neoplasms
Monoclonal antibodies and prostate-specific membrane antigen.
Prostatic Neoplasms
More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.
Prostatic Neoplasms
More than the prostate: Intrapancreatic accessory spleen and papillary thyroid cancer detected with 18F-PSMA PET/CT.
Prostatic Neoplasms
Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview.
Prostatic Neoplasms
Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII.
Prostatic Neoplasms
Mri-based cancer lesion analysis with 3d printed patient specific prostate cutting guides.
Prostatic Neoplasms
Multi-component Polymeric System for Tumour Cell-Specific Gene Delivery Using a Universal Bungarotoxin Linker.
Prostatic Neoplasms
Multi-Modal PET and MR Imaging in the Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) Model for Initial in Vivo Testing of Target-Specific Radioligands.
Prostatic Neoplasms
Multianalyte quantitative competitive PCR on optically encoded microspheres for an eight-gene panel related to prostate cancer.
Prostatic Neoplasms
Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging.
Prostatic Neoplasms
Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer.
Prostatic Neoplasms
Multimodality Image Fusion with PSMA PET/CT and High-Intensity Focused Ultrasound Focal Therapy for Primary Diagnosis and Management of Prostate Cancer: A Planned Research Initiative.
Prostatic Neoplasms
Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting.
Prostatic Neoplasms
Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice.
Prostatic Neoplasms
N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
Prostatic Neoplasms
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy.
Prostatic Neoplasms
Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer.
Prostatic Neoplasms
Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.
Prostatic Neoplasms
Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression.
Prostatic Neoplasms
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Prostatic Neoplasms
Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody.
Prostatic Neoplasms
New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells.
Prostatic Neoplasms
New circulating biomarkers for prostate cancer.
Prostatic Neoplasms
New frontiers in focal therapy for prostate cancer: Prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging.
Prostatic Neoplasms
New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography.
Prostatic Neoplasms
New Imaging Techniques in Prostate Cancer.
Prostatic Neoplasms
New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide.
Prostatic Neoplasms
New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen.
Prostatic Neoplasms
New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
Prostatic Neoplasms
Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments.
Prostatic Neoplasms
Next revolution in molecular theranostics: personalized medicine for urologic cancers.
Prostatic Neoplasms
NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.
Prostatic Neoplasms
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Prostatic Neoplasms
Non-prostate uptake on 18F-PSMA-1007 PET/CT: a case of myeloma.
Prostatic Neoplasms
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
Prostatic Neoplasms
Nonspecific Uptake of 68Ga-Prostate-Specific Membrane Antigen in Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of Literature.
Prostatic Neoplasms
Novel ?- and ?-Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen.
Prostatic Neoplasms
Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer.
Prostatic Neoplasms
Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
Prostatic Neoplasms
Novel multifunctional 18F-labelled PET tracer with prostate-specific membrane antigen-targeting and hypoxia-sensitive moieties.
Prostatic Neoplasms
Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.
Prostatic Neoplasms
Novel prostate-specific promoter derived from PSA and PSMA enhancers.
Prostatic Neoplasms
Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness.
Prostatic Neoplasms
Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Prostatic Neoplasms
Oligometastasis to testis in prostate cancer: Role of gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography.
Prostatic Neoplasms
Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.
Prostatic Neoplasms
Oligometastatic prostate cancer: Metastases-directed therapy?
Prostatic Neoplasms
One-pot synthesis of carbon dots with intrinsic folic acid for synergistic imaging-guided photothermal therapy of prostate cancer cells.
Prostatic Neoplasms
One-step 18F-labeling and preclinical evaluation of prostate specific membrane antigen trifluoroborate probes for cancer imaging.
Prostatic Neoplasms
Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate Cancer.
Prostatic Neoplasms
Optimization of Labeling PSMA(HBED) with Ethanol-Postprocessed (68)Ga and Its Quality Control Systems.
Prostatic Neoplasms
Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer.
Prostatic Neoplasms
Optimized Anti-Prostate-Specific Membrane Antigen Single-Chain Variable Fragment-Loaded Nanobubbles as a Novel Targeted Ultrasound Contrast Agent for the Diagnosis of Prostate Cancer.
Prostatic Neoplasms
Other biomarkers for detecting prostate cancer.
Prostatic Neoplasms
Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis.
Prostatic Neoplasms
Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy.
Prostatic Neoplasms
Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner.
Prostatic Neoplasms
Pancreatic Ductal Adenocarcinoma With High Radiotracer Uptake in 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Prostatic Neoplasms
Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility.
Prostatic Neoplasms
Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes.
Prostatic Neoplasms
Patterns of primary staging for newly diagnosed prostate cancer in the era of prostate specific membrane antigen positron emission tomography: A population-based analysis.
Prostatic Neoplasms
Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer.
Prostatic Neoplasms
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.
Prostatic Neoplasms
PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Prostatic Neoplasms
PEGylated J591 mAb loaded in PLGA-PEG-PLGA tri-block copolymer for targeted delivery: in vitro evaluation in human prostate cancer cells.
Prostatic Neoplasms
Penile Metastasis from Prostate Cancer Presenting as Malignant Priapism Detected Using Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
Prostatic Neoplasms
Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis.
Prostatic Neoplasms
Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis.
Prostatic Neoplasms
Perineum and penile invasion of recurrent prostate carcinoma shown by Ga-68 PSMA PET/CT.
Prostatic Neoplasms
PET imaging in prostate cancer: focus on prostate-specific membrane antigen.
Prostatic Neoplasms
PET imaging in urology: a rapidly growing successful collaboration.
Prostatic Neoplasms
PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Prostatic Neoplasms
PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Prostatic Neoplasms
PET/CT Imaging and Radioimmunotherapy of Prostate Cancer.
Prostatic Neoplasms
PET/CT imaging of prostate cancer in the era of small molecule prostate specific membrane antigen targeted tracers.
Prostatic Neoplasms
Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
Prostatic Neoplasms
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Prostatic Neoplasms
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Phase 2 study of (99m)Tc-trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic lymph node dissection.
Prostatic Neoplasms
Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen.
Prostatic Neoplasms
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
Prostatic Neoplasms
Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer.
Prostatic Neoplasms
Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).
Prostatic Neoplasms
Phosphinic Acid Functionalized Polyazacycloalkane Chelators for Radiodiagnostics and Radiotherapeutics: Unique Characteristics and Applications.
Prostatic Neoplasms
Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen.
Prostatic Neoplasms
Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT.
Prostatic Neoplasms
Pitfalls in Gallium-68 PSMA PET/CT Interpretation-A Pictorial Review.
Prostatic Neoplasms
Plasma enabled devices for the selective capture and photodynamic identification of prostate cancer cells.
Prostatic Neoplasms
Plumbagin-loaded aptamer-targeted poly D,L-lactic-co-glycolic acid-b-polyethylene glycol nanoparticles for prostate cancer therapy.
Prostatic Neoplasms
PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer.
Prostatic Neoplasms
Polymeric nanoparticles for drug delivery.
Prostatic Neoplasms
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy.
Prostatic Neoplasms
Positive Multifocal PSMA PET/CT in a Patient With Prostate Cancer and Follicular Lymphoma.
Prostatic Neoplasms
Positron emission tomography (PET) radiotracers for prostate cancer imaging.
Prostatic Neoplasms
Positron Emission Tomography-computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer.
Prostatic Neoplasms
Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
Prostatic Neoplasms
Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?
Prostatic Neoplasms
Positron-emission tomography imaging in urological oncology: Current aspects and developments.
Prostatic Neoplasms
Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Prostatic Neoplasms
Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years.
Prostatic Neoplasms
Potential of radiolabelled PSMA PET/CT or PET/MRI diagnostic procedures in gliomas/glioblastomas.
Prostatic Neoplasms
Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness.
Prostatic Neoplasms
Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Prostatic Neoplasms
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.
Prostatic Neoplasms
Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
Prostatic Neoplasms
Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
Prostatic Neoplasms
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Prostatic Neoplasms
Preclinical evaluation and pilot clinical study of Al18F-PSMA-BCH for prostate cancer imaging.
Prostatic Neoplasms
Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer.
Prostatic Neoplasms
Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer.
Prostatic Neoplasms
Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.
Prostatic Neoplasms
Preclinical Evaluation of a Fluorine-18 Labeled Probe for the Detection of the Expression of PSMA Level in Cancer.
Prostatic Neoplasms
Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for 64Cu/67Cu-Based Theranostics in Prostate Cancer.
Prostatic Neoplasms
Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.
Prostatic Neoplasms
Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
Prostatic Neoplasms
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Prostatic Neoplasms
Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer.
Prostatic Neoplasms
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Prostatic Neoplasms
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.
Prostatic Neoplasms
Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer.
Prostatic Neoplasms
Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.
Prostatic Neoplasms
Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [
Prostatic Neoplasms
Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix.
Prostatic Neoplasms
Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.
Prostatic Neoplasms
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease.
Prostatic Neoplasms
Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
Prostatic Neoplasms
Preparation and Biological Evaluation of [99mTc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer.
Prostatic Neoplasms
Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA).
Prostatic Neoplasms
Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer.
Prostatic Neoplasms
Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity.
Prostatic Neoplasms
Procedures for the GMP-Compliant Production and Quality Control of [
Prostatic Neoplasms
Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy.
Prostatic Neoplasms
Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells.
Prostatic Neoplasms
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy.
Prostatic Neoplasms
Prognostic importance of PSA response in patients who received Lutetium-177 PSMA treatment for castration resistant prostate cancer.
Prostatic Neoplasms
Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Prostatic Neoplasms
Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells.
Prostatic Neoplasms
Prospective Evaluation of 18F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI.
Prostatic Neoplasms
Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis.
Prostatic Neoplasms
Prospective Validation of Gallium-68 PSMA-PET/CT in Primary Staging of Prostate Cancer Patients.
Prostatic Neoplasms
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
Prostatic Neoplasms
ProstaScint(R) Scan: Contemporary Use in Clinical Practice.
Prostatic Neoplasms
Prostate cancer cells show a nearly 100-fold increase in the expression of the longer of two alternatively spliced mRNAs of the prostate-specific membrane antigen (PSM)
Prostatic Neoplasms
Prostate Cancer Imaging with Novel PET Tracers.
Prostatic Neoplasms
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT.
Prostatic Neoplasms
Prostate cancer nodal oligometastasis accurately assessed using prostate-specific membrane antigen positron emission tomography-computed tomography and confirmed histologically following robotic-assisted lymph node dissection.
Prostatic Neoplasms
Prostate cancer PET tracers: essentials for the urologist.
Prostatic Neoplasms
Prostate Cancer Targeted X-Ray Fluorescence Imaging via Gold Nanoparticles Functionalized With Prostate-Specific Membrane Antigen (PSMA).
Prostatic Neoplasms
Prostate cancer targeting motifs: Expression of ?(?) ?(3) , neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts.
Prostatic Neoplasms
Prostate cancer vaccines: current status and future potential.
Prostatic Neoplasms
Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
Prostatic Neoplasms
Prostate penile metastasis: Incidence and imaging pattern on 68 Ga-PSMA PET/CT.
Prostatic Neoplasms
Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer.
Prostatic Neoplasms
Prostate specific membrane antigen (PSM) is expressed in various human tissues: implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread.
Prostatic Neoplasms
Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?
Prostatic Neoplasms
Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro.
Prostatic Neoplasms
Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis.
Prostatic Neoplasms
Prostate specific membrane antigen (PSMA) from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer.
Prostatic Neoplasms
Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro.
Prostatic Neoplasms
Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Prostatic Neoplasms
Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.
Prostatic Neoplasms
Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway.
Prostatic Neoplasms
Prostate specific membrane antigen mRNA in blood as a potential predictor of biochemical recurrence after radical prostatectomy.
Prostatic Neoplasms
Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer.
Prostatic Neoplasms
Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
Prostatic Neoplasms
Prostate Specific Membrane Antigen Targeted (18)F-DCFPyL Positron Emission Tomography/Computerized Tomography in the Preoperative Staging of Men with High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.
Prostatic Neoplasms
Prostate specific membrane antigen- a target for imaging and therapy with radionuclides.
Prostatic Neoplasms
Prostate specific membrane antigen: the role in salvage lymph node dissection and radio-ligand therapy.
Prostatic Neoplasms
Prostate targeting ligands based on N-acetylated alpha-linked acidic dipeptidase.
Prostatic Neoplasms
Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
Prostatic Neoplasms
Prostate-specific antigen and new related markers for prostate cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen (FOLH1): recent advances in characterising this putative prostate cancer gene.
Prostatic Neoplasms
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo".
Prostatic Neoplasms
Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells.
Prostatic Neoplasms
Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck.
Prostatic Neoplasms
Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review.
Prostatic Neoplasms
Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls.
Prostatic Neoplasms
Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen (PSMA): current benefits and future value.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Accumulation in Lower Extremity Lymphedema.
Prostatic Neoplasms
Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics.
Prostatic Neoplasms
Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen and its truncated form PSM'.
Prostatic Neoplasms
Prostate-specific membrane antigen as a target for cancer imaging and therapy.
Prostatic Neoplasms
Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability.
Prostatic Neoplasms
Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity.
Prostatic Neoplasms
Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer.
Prostatic Neoplasms
Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications.
Prostatic Neoplasms
Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice.
Prostatic Neoplasms
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.
Prostatic Neoplasms
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
Prostatic Neoplasms
Prostate-specific membrane antigen expression in melanoma metastases.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Expression in Primary Juvenile Nasal Angiofibroma-A Pilot Study.
Prostatic Neoplasms
Prostate-specific membrane antigen expression in the duodenum: implications in coeliac disease and immunotherapy for prostate cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers.
Prostatic Neoplasms
Prostate-specific membrane antigen expression predicts prostate cancer recurrence.
Prostatic Neoplasms
Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Prostatic Neoplasms
Prostate-specific membrane antigen for the surgical oncologist: interpreting expression beyond the prostate.
Prostatic Neoplasms
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
Prostatic Neoplasms
Prostate-specific Membrane Antigen Imaging and Theranostics Impact Patient Outcomes.
Prostatic Neoplasms
Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond.
Prostatic Neoplasms
Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
Prostatic Neoplasms
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen PET for Assessment of Primary and Recurrent Prostate Cancer with Histopathology as Reference Standard: A Systematic Review and Meta-Analysis.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges.
Prostatic Neoplasms
Prostate-specific Membrane Antigen PET in Prostate Cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Prostatic Neoplasms
Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy.
Prostatic Neoplasms
Prostate-specific membrane antigen PET/MRI validation of MR textural analysis for detection of transition zone prostate cancer.
Prostatic Neoplasms
Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Prostatic Neoplasms
Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy.
Prostatic Neoplasms
Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.
Prostatic Neoplasms
Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning.
Prostatic Neoplasms
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Prostatic Neoplasms
Prostate-specific Membrane Antigen Positron Emission Tomography-guided Radiotherapy.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Positron Emission Tomography-Identified Para-aortic Prostate Cancer Recurrence After Surgery and Salvage Radiation Therapy.
Prostatic Neoplasms
Prostate-specific membrane antigen positron emission tomography/computed tomography combined with sentinel node biopsy for primary lymph node staging in prostate cancer.
Prostatic Neoplasms
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Locally Advanced, Recurrent, and Metastatic Prostate Cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.
Prostatic Neoplasms
Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate Cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen radioligand therapy of prostate cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: does size matter for targeted particles?
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing Ligand.
Prostatic Neoplasms
Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence.
Prostatic Neoplasms
Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Targeted Polymersomes for Delivering Mocetinostat and Docetaxel to Prostate Cancer Cell Spheroids.
Prostatic Neoplasms
Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Prostatic Neoplasms
Prostate-specific Membrane Antigen Theranostics for Prostate Cancer Care: A Need to Prove Clinical Utility.
Prostatic Neoplasms
Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option.
Prostatic Neoplasms
Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen-derived primers in a nested reverse transcription polymerase chain reaction for detecting prostatic cancer cells.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen-Guided Surgery.
Prostatic Neoplasms
Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.
Prostatic Neoplasms
Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer.
Prostatic Neoplasms
Prostate-specific membrane antigen-targeted liposomes specifically deliver the Zn(2+) chelator TPEN inducing oxidative stress in prostate cancer cells.
Prostatic Neoplasms
Prostate-specific membrane antigen-targeted photoacoustic imaging of prostate cancer in vivo.
Prostatic Neoplasms
Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives.
Prostatic Neoplasms
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Prostatic Neoplasms
Prostate-Specific Membrane Antigen: Much More Than a Prostate Cancer Marker.
Prostatic Neoplasms
Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer.
Prostatic Neoplasms
Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice.
Prostatic Neoplasms
Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Prostatic Neoplasms
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma.
Prostatic Neoplasms
PSA targeted dual-modality manganese oxide-mesoporous silica nanoparticles for prostate cancer imaging.
Prostatic Neoplasms
PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
Prostatic Neoplasms
PSA-stratified performance of 18F- and 68Ga-labeled tracers in PSMA-PET imaging of patients with biochemical recurrence of prostate cancer.
Prostatic Neoplasms
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Prostatic Neoplasms
PSMA Antibody-Conjugated Pentablock Copolymer Nanomicellar Formulation for Targeted Delivery to Prostate Cancer.
Prostatic Neoplasms
PSMA brings new flavors to PI3K signaling: A role for glutamate in prostate cancer.
Prostatic Neoplasms
PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.
Prostatic Neoplasms
PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?
Prostatic Neoplasms
PSMA expression in the Hi-Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool.
Prostatic Neoplasms
PSMA Expression in Tumor Neovasculature Endothelial Cells of Follicular Thyroid Adenoma as Identified by Molecular Imaging Using 68Ga-PSMA Ligand PET/CT.
Prostatic Neoplasms
PSMA expression is highly homogenous in primary prostate cancer.
Prostatic Neoplasms
PSMA ligands in prostate cancer - Probe optimization and theranostic applications.
Prostatic Neoplasms
PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response.
Prostatic Neoplasms
PSMA PET/CT and staging high risk prostate cancer: a non-systematic review of high clinical impact literature.
Prostatic Neoplasms
PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications.
Prostatic Neoplasms
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.
Prostatic Neoplasms
PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer.
Prostatic Neoplasms
PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Prostatic Neoplasms
PSMA Theranostics: A "Must Have" in Every Prostate Cancer Center. Illustration of Two Clinical Cases and Review of the Literature.
Prostatic Neoplasms
PSMA Theranostics: Current Status and Future Directions.
Prostatic Neoplasms
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy.
Prostatic Neoplasms
PSMA Theranostics: Science and Practice.
Prostatic Neoplasms
PSMA Uptake in Mediastinal Sarcoidosis.
Prostatic Neoplasms
PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy.
Prostatic Neoplasms
PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
Prostatic Neoplasms
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Prostatic Neoplasms
PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model.
Prostatic Neoplasms
PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses.
Prostatic Neoplasms
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy.
Prostatic Neoplasms
PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking.
Prostatic Neoplasms
PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.
Prostatic Neoplasms
PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years.
Prostatic Neoplasms
PSMA-PET guided hook-wire localization of nodal metastases in prostate cancer: a targeted approach.
Prostatic Neoplasms
PSMA-PET identifies PCWG3 target populations with superior accuracy and reproducibility when compared to conventional imaging: a multicenter retrospective study.
Prostatic Neoplasms
PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy.
Prostatic Neoplasms
PSMA-positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state.
Prostatic Neoplasms
PSMA-targeted contrast agents for intraoperative imaging of prostate cancer.
Prostatic Neoplasms
PSMA-targeted dendrimers: a patent evaluation (WO2012078534).
Prostatic Neoplasms
PSMA-targeted melanin-like nanoparticles as a multifunctional nanoplatform for prostate cancer theranostics.
Prostatic Neoplasms
PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617.
Prostatic Neoplasms
PSMA-Targeted Radiotherapy Extends Survival.
Prostatic Neoplasms
PSMA-targeted SPECT agents: Mode of binding effect on in vitro performance.
Prostatic Neoplasms
PSMA-Targeted Stably Linked "Dendrimer-Glutamate Urea-Methotrexate" as a Prostate Cancer Therapeutic.
Prostatic Neoplasms
Psma/Psa ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
Prostatic Neoplasms
Pulmonary Opacities and Bronchiectasis Avid on 68Ga-PSMA PET.
Prostatic Neoplasms
Pulmonary Vein Varix Mimicking Prostate Cancer Metastasis on 68Ga-Prostate Specific Membrane Antigen-11 PET/CT.
Prostatic Neoplasms
Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography.
Prostatic Neoplasms
Quality control and GMP synthesis of 68Ga-prostate-specific membrane antigen-11 for detection of low- and high-grade prostate cancer.
Prostatic Neoplasms
Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR.
Prostatic Neoplasms
Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients.
Prostatic Neoplasms
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.
Prostatic Neoplasms
Quantum dots for in vivo molecular and cellular imaging.
Prostatic Neoplasms
Radiation dosimetry and biodistribution of 18F-PSMA-11 for PET imaging of prostate cancer.
Prostatic Neoplasms
Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.
Prostatic Neoplasms
Radiation Dosimetry for (177)Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions.
Prostatic Neoplasms
Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.
Prostatic Neoplasms
Radiochemistry and Preclinical PET Imaging of
Prostatic Neoplasms
Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer.
Prostatic Neoplasms
Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro.
Prostatic Neoplasms
Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Prostatic Neoplasms
Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.
Prostatic Neoplasms
Radioimmunotherapy of Metastatic Prostate Cancer with ¹??Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
Prostatic Neoplasms
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
Prostatic Neoplasms
Radioiodine therapy for castration-resistant prostate cancer following prostate-specific membrane antigen promoter-mediated transfer of the human sodium iodide symporter.
Prostatic Neoplasms
Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Prostatic Neoplasms
Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA.
Prostatic Neoplasms
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Prostatic Neoplasms
Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.
Prostatic Neoplasms
Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis.
Prostatic Neoplasms
Radiolabelled PSMA PET/CT in breast cancer. A systematic review.
Prostatic Neoplasms
Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90Y-DOTA-EB-MCG.
Prostatic Neoplasms
Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Prostatic Neoplasms
Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
Prostatic Neoplasms
Radiopharmaceutical Therapy.
Prostatic Neoplasms
Radiotheranostics Using a Novel 225Ac-Labeled Radioligand with Improved Pharmacokinetics Targeting Prostate-Specific Membrane Antigen.
Prostatic Neoplasms
Rapid modulation of PSMA expression by Androgen deprivation: Serial 68Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade.
Prostatic Neoplasms
Rare Sites of Metastases in Prostate Cancer Detected on Ga-68 PSMA PET/CT Scan-A Case Series.
Prostatic Neoplasms
Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery.
Prostatic Neoplasms
Rationally Designed Sulfamides As Glutamate Carboxypeptidase II (GCPII) Inhibitors.
Prostatic Neoplasms
Re: 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
Prostatic Neoplasms
Re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028.
Prostatic Neoplasms
Re: Isabel Rauscher, Charlotte Düwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol 2018;73:656-61: Clinical Significance of Prostate-specific Membrane Antigen Immunohistochemistry and Role of the Uropathologists.
Prostatic Neoplasms
Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. Lancet 2020;395:1208-16: PSMA Positron Emission Tomography: One Tracer Fixes Them All!
Prostatic Neoplasms
Re: Prostate cancer targeting motifs: expression of ?? ?3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts.
Prostatic Neoplasms
Re: Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
Prostatic Neoplasms
Re: Prostate-specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-resistant Prostate Cancer.
Prostatic Neoplasms
Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study.
Prostatic Neoplasms
Re: Prostate-Specific Membrane Antigen PET-CT in Patients with High-Risk Prostate Cancer before Curative-Intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.
Prostatic Neoplasms
Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.
Prostatic Neoplasms
Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods.
Prostatic Neoplasms
Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis.
Prostatic Neoplasms
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Recent Advances in Prostate Cancer Treatment and Drug Discovery.
Prostatic Neoplasms
Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals.
Prostatic Neoplasms
Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT.
Prostatic Neoplasms
Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells.
Prostatic Neoplasms
Recombinant glutamate carboxypeptidase II (prostate specific membrane antigen--PSMA)--cellular localization and bioactivity analyses.
Prostatic Neoplasms
Recovery of Renal Function Under PSMA Mediated Radioligand Therapy of Advanced Metastasized Castration Resistant Prostate Cancer.
Prostatic Neoplasms
Rectal Carcinoma on 68Ga-PSMA PET/CT.
Prostatic Neoplasms
Recurrent Medullary Thyroid Carcinoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT: Exploring New Theranostic Avenues.
Prostatic Neoplasms
Reduction of (68)Ga-PSMA renal uptake with mannitol infusion: preliminary results.
Prostatic Neoplasms
Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Prostatic Neoplasms
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Prostatic Neoplasms
Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer.
Prostatic Neoplasms
Renal Pelvis Metastasis From Prostatic Adenocarcinoma Missed by PSMA PET: A Case Report.
Prostatic Neoplasms
Repeatability of 68Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
Prostatic Neoplasms
Repeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
Prostatic Neoplasms
Repeatability of tumor blood flow quantification with 82Rubidium PET/CT in prostate cancer - a test-retest study.
Prostatic Neoplasms
Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen.
Prostatic Neoplasms
Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028: Despite its Slightly Limited Specificity, Prostate-specific Membrane Antigen Imaging is Still a Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
Prostatic Neoplasms
Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).
Prostatic Neoplasms
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy.
Prostatic Neoplasms
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.
Prostatic Neoplasms
Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy.
Prostatic Neoplasms
Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy.
Prostatic Neoplasms
Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer.
Prostatic Neoplasms
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.
Prostatic Neoplasms
Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer.
Prostatic Neoplasms
Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.
Prostatic Neoplasms
Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread.
Prostatic Neoplasms
Rib Fractures Mimicking Bone Metastases in 18F-PSMA-1007 PET/CT for Prostate Cancer.
Prostatic Neoplasms
RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Prostatic Neoplasms
Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review.
Prostatic Neoplasms
Role of Early Dynamic Positron Emission Tomography/Computed Tomography with 68Ga-prostate-specific Membrane Antigen-HBED-CC in Patients with Adenocarcinoma Prostate: Initial Results.
Prostatic Neoplasms
Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer.
Prostatic Neoplasms
Role of novel imaging in the management of prostate cancer.
Prostatic Neoplasms
Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer.
Prostatic Neoplasms
Role of salvage lymph node dissection in prostate cancer.
Prostatic Neoplasms
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Prostatic Neoplasms
Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status.
Prostatic Neoplasms
Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.
Prostatic Neoplasms
Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.
Prostatic Neoplasms
Schwannoma Showing Avid Uptake on 68Ga-PSMA-HBED-CC PET/CT.
Prostatic Neoplasms
Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Prostatic Neoplasms
Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Prostatic Neoplasms
Seek and Find: Current Prospective Evidence for Prostate-specific Membrane Antigen Imaging to Detect Recurrent Prostate Cancer.
Prostatic Neoplasms
Selective gene therapy for prostate cancer cells using liposomes conjugated with IgM type monoclonal antibody against prostate-specific membrane antigen.
Prostatic Neoplasms
Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer.
Prostatic Neoplasms
Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake.
Prostatic Neoplasms
Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Prostatic Neoplasms
Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.
Prostatic Neoplasms
Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device.
Prostatic Neoplasms
Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate-Specific Membrane Antigen.
Prostatic Neoplasms
Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
Prostatic Neoplasms
Simple new method for labelling of PSMA-11 with 68Ga in NaHCO3.
Prostatic Neoplasms
Simple, mild, one-step labelling of proteins with gallium-68 using a tris(hydroxypyridinone) bifunctional chelator: a
Prostatic Neoplasms
Simplified Methods for Quantification of 18F-DCFPyL Uptake in Patients with Prostate Cancer.
Prostatic Neoplasms
Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.
Prostatic Neoplasms
Simultaneous detection of circulating prostate specific antigen (PSA)-expressing and prostate specific membrane antigen (PSM)-expressing cells by a multiplex reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Prostatic Neoplasms
Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
Prostatic Neoplasms
Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
Prostatic Neoplasms
Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer.
Prostatic Neoplasms
Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer.
Prostatic Neoplasms
Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells.
Prostatic Neoplasms
Size Matters: Arginine-Derived Peptides Targeting the PSMA Receptor Can Efficiently Complex but Not Transfect siRNA.
Prostatic Neoplasms
Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer.
Prostatic Neoplasms
Soft tissue metastasis of the penis detected by copper-64 labeled prostate-specific membrane antigen positron emission tomography (64Cu-PSMA PET/CT) in a patient with prostate cancer.
Prostatic Neoplasms
Solitary castrate-resistant prostate cancer metastasis to adrenal gland with concordant intense avidity on PSMA and FDG PET.
Prostatic Neoplasms
Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68 Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant?
Prostatic Neoplasms
Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen.
Prostatic Neoplasms
Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
Prostatic Neoplasms
Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer.
Prostatic Neoplasms
Spectroscopy-Assisted Label-free Molecular Analysis of Live Cell Surface with Vertically Aligned Plasmonic Nanopillars.
Prostatic Neoplasms
Spinal Tuberculosis Mimicking as Prostate Cancer Metastases in Ga-68 Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography.
Prostatic Neoplasms
Spotlight on PSMA as a new theranostic biomarker for bladder cancer.
Prostatic Neoplasms
Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical.
Prostatic Neoplasms
Standardization of the [68Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer.
Prostatic Neoplasms
State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer.
Prostatic Neoplasms
Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Prostatic Neoplasms
Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer.
Prostatic Neoplasms
Structural characterization of P1'-diversified urea-based inhibitors of glutamate carboxypeptidase II.
Prostatic Neoplasms
Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III.
Prostatic Neoplasms
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Prostatic Neoplasms
Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.
Prostatic Neoplasms
Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from ?-amino acid with (S)- or (R)-configuration at P1' region.
Prostatic Neoplasms
Structure-activity relationships of 2',5'-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists.
Prostatic Neoplasms
Structure-activity relationships of succinimidyl-Cys-C(O)-Glu derivatives with different near-infrared fluorophores as optical imaging probes for prostate-specific membrane antigen.
Prostatic Neoplasms
Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
Prostatic Neoplasms
Sub-nanomolar detection of prostate-specific membrane antigen in synthetic urine by synergistic, dual-ligand phage.
Prostatic Neoplasms
Suramin potently inhibits the enzymatic activity of PSM.
Prostatic Neoplasms
Surface Modification of Liposomes by a Lipopolymer Targeting Prostate Specific Membrane Antigen for Theranostic Delivery in Prostate Cancer.
Prostatic Neoplasms
Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
Prostatic Neoplasms
SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
Prostatic Neoplasms
Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
Prostatic Neoplasms
Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.
Prostatic Neoplasms
Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer.
Prostatic Neoplasms
Synthesis and Binding of a Novel PSMA-specific Conjugate.
Prostatic Neoplasms
Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
Prostatic Neoplasms
Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Prostatic Neoplasms
Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA.
Prostatic Neoplasms
Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.
Prostatic Neoplasms
Synthesis and Biological Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for Positron Emission Tomography of Prostate Cancer.
Prostatic Neoplasms
Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them.
Prostatic Neoplasms
Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates.
Prostatic Neoplasms
Synthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen.
Prostatic Neoplasms
Synthesis and Evaluation of 68Ga- and 177Lu-Labeled (R)- vs (S)-DOTAGA Prostate-Specific Membrane Antigen-Targeting Derivatives.
Prostatic Neoplasms
Synthesis and evaluation of a novel near-infrared fluorescent probe based on succinimidyl-Cys-C(O)-Glu that targets prostate-specific membrane antigen for optical imaging.
Prostatic Neoplasms
Synthesis and evaluation of a novel urea-based
Prostatic Neoplasms
Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen.
Prostatic Neoplasms
Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen.
Prostatic Neoplasms
Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of PSMA and Hypoxia for Prostate Cancer.
Prostatic Neoplasms
Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer.
Prostatic Neoplasms
Synthesis and evaluation of tumor-homing peptides for targeting prostate cancer.
Prostatic Neoplasms
Synthesis and evaluation of [(64)Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer.
Prostatic Neoplasms
Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity.
Prostatic Neoplasms
Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer.
Prostatic Neoplasms
Synthesis and in vitro preliminary evaluation of prostate-specific membrane antigen targeted upconversion nanoparticles as a first step towards radio/fluorescence-guided surgery of prostate cancer.
Prostatic Neoplasms
Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
Prostatic Neoplasms
Synthesis and positron emission tomography evaluation of (18)F-Glu-Urea-Lys, a prostate-specific membrane antigen-based imaging agent for prostate cancer.
Prostatic Neoplasms
Synthesis and preclinical evaluation of 68Ga-PSMA-BCH for prostate cancer imaging.
Prostatic Neoplasms
Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007.
Prostatic Neoplasms
Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.
Prostatic Neoplasms
Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
Prostatic Neoplasms
Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer.
Prostatic Neoplasms
Synthesis and SAR of ??mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates.
Prostatic Neoplasms
Synthesis of KUE-siRNA Conjugates for Prostate Cancer Cell-Targeted Gene Silencing.
Prostatic Neoplasms
Synthesis of novel multivalent fluorescent inhibitors with high affinity to prostate cancer and their biological evaluation.
Prostatic Neoplasms
Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion.
Prostatic Neoplasms
Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep.
Prostatic Neoplasms
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
Prostatic Neoplasms
Targeted ?-therapy in non-prostate malignancies.
Prostatic Neoplasms
Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen).
Prostatic Neoplasms
Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells.
Prostatic Neoplasms
Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo.
Prostatic Neoplasms
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Prostatic Neoplasms
Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.
Prostatic Neoplasms
Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors.
Prostatic Neoplasms
Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Prostatic Neoplasms
Targeted Inhibition of Prostate Cancer Metastases with an RNA Aptamer to Prostate-specific Membrane Antigen.
Prostatic Neoplasms
Targeted Nanobubbles Carrying Indocyanine Green for Ultrasound, Photoacoustic and Fluorescence Imaging of Prostate Cancer.
Prostatic Neoplasms
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
Prostatic Neoplasms
Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy.
Prostatic Neoplasms
Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
Prostatic Neoplasms
Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway.
Prostatic Neoplasms
Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer.
Prostatic Neoplasms
Targeted Prostate Biopsy Using (68)Gallium PSMA-PET/CT for Image Guidance.
Prostatic Neoplasms
Targeted radionuclide therapy: an emerging field in solid tumours.
Prostatic Neoplasms
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
Prostatic Neoplasms
Targeted therapies for prostate cancer against the prostate specific membrane antigen.
Prostatic Neoplasms
Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
Prostatic Neoplasms
Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody.
Prostatic Neoplasms
Targeting human prostate cancer with (111) In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
Prostatic Neoplasms
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
Prostatic Neoplasms
Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.
Prostatic Neoplasms
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.
Prostatic Neoplasms
Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).
Prostatic Neoplasms
Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.
Prostatic Neoplasms
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.
Prostatic Neoplasms
Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy.
Prostatic Neoplasms
Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
Prostatic Neoplasms
Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
Prostatic Neoplasms
Targeting prostate-specific membrane antigen in cancer therapy: can molecular medicine be brought to the surface?
Prostatic Neoplasms
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.
Prostatic Neoplasms
Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
Prostatic Neoplasms
Targeting thapsigargin towards tumors.
Prostatic Neoplasms
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.
Prostatic Neoplasms
Targeting the prostate-specific membrane antigen for prostate cancer therapy.
Prostatic Neoplasms
Targeting the spectrum of immune checkpoints in prostate cancer.
Prostatic Neoplasms
Tc-99m-PSMA imaging allows successful radioguided surgery in recurrent prostate cancer.
Prostatic Neoplasms
Technology evaluation: MLN-591, Cornell University/BZL Biologics/ImmunoGen/Millennium.
Prostatic Neoplasms
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
Prostatic Neoplasms
Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
Prostatic Neoplasms
The (68)Ga/(177)Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates.
Prostatic Neoplasms
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Prostatic Neoplasms
The application of the RT-PCR method for the staging of the prostate cancer progression.
Prostatic Neoplasms
The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients.
Prostatic Neoplasms
The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.
Prostatic Neoplasms
The emergence of radioimmunoscintigraphy for prostate cancer.
Prostatic Neoplasms
The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer.
Prostatic Neoplasms
The emerging value of 64Cu for molecular imaging and therapy.
Prostatic Neoplasms
The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer.
Prostatic Neoplasms
The expression of prostate-specific membrane antigen in peripheral blood leukocytes.
Prostatic Neoplasms
The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.
Prostatic Neoplasms
The frequency of thyroid incidental findings and risk of malignancy detected by 68Ga-labeled prostate-specific membrane antigen PET/CT in prostate cancer.
Prostatic Neoplasms
The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research.
Prostatic Neoplasms
The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study.
Prostatic Neoplasms
The impact of [
Prostatic Neoplasms
The influence of 68Ga-prostate-specific membrane antigen PET/computed tomography on prostate cancer staging and planning of definitive radiation therapy.
Prostatic Neoplasms
The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer.
Prostatic Neoplasms
The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.
Prostatic Neoplasms
The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
Prostatic Neoplasms
The Proinflammatory Cytokine, IL-6, and its Interference with bFGF Signaling and PSMA in Prostate Cancer Cells.
Prostatic Neoplasms
The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer.
Prostatic Neoplasms
The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research.
Prostatic Neoplasms
The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.
Prostatic Neoplasms
The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
Prostatic Neoplasms
The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Prostatic Neoplasms
The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer
Prostatic Neoplasms
The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery.
Prostatic Neoplasms
The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients.
Prostatic Neoplasms
The Role of Magnetic Resonance Imaging in (Future) Cancer Staging: Note the Nodes.
Prostatic Neoplasms
The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy.
Prostatic Neoplasms
The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Prostatic Neoplasms
The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.
Prostatic Neoplasms
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature.
Prostatic Neoplasms
The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer.
Prostatic Neoplasms
The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
Prostatic Neoplasms
The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far.
Prostatic Neoplasms
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Prostatic Neoplasms
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Prostatic Neoplasms
The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer.
Prostatic Neoplasms
The use of 68Ga prostate-specific membrane antigen PET-CT in prostate cancer: diagnostic challenges and therapeutic opportunities.
Prostatic Neoplasms
The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations.
Prostatic Neoplasms
The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma.
Prostatic Neoplasms
The utility of radiolabeled PSMA ligands for tumor imaging.
Prostatic Neoplasms
The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.
Prostatic Neoplasms
Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
Prostatic Neoplasms
Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Prostatic Neoplasms
Theranostics in oncology: What radiologists want to know.
Prostatic Neoplasms
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
Prostatic Neoplasms
Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine.
Prostatic Neoplasms
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
Prostatic Neoplasms
Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.
Prostatic Neoplasms
Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu.
Prostatic Neoplasms
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
Prostatic Neoplasms
Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
Prostatic Neoplasms
Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.
Prostatic Neoplasms
Thyroid Incidentaloma on 18F-fluorocholine PET/CT and 68Ga-PSMA PET/CT Revealing a Medullary Thyroid Carcinoma.
Prostatic Neoplasms
Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs.
Prostatic Neoplasms
Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer().
Prostatic Neoplasms
Tobacco mosaic virus for the targeted delivery of drugs to cells expressing prostate-specific membrane antigen.
Prostatic Neoplasms
Toward 18 F-Labeled Theranostics: A Single Agent that Can Be Labeled with 18 F, 64 Cu, or 177 Lu.
Prostatic Neoplasms
Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Prostatic Neoplasms
Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
Prostatic Neoplasms
Translational Molecular Imaging of Prostate Cancer.
Prostatic Neoplasms
Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer.
Prostatic Neoplasms
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.
Prostatic Neoplasms
Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002).
Prostatic Neoplasms
Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents.
Prostatic Neoplasms
Tumor detection of 18F-PSMA-1007 in the prostate gland in patients with prostate cancer using prostatectomy specimens as reference method.
Prostatic Neoplasms
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
Prostatic Neoplasms
Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?
Prostatic Neoplasms
Two-step transcriptional amplification-lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer.
Prostatic Neoplasms
Ultrahigh affinity Raman probe for targeted live cell imaging of prostate cancer.
Prostatic Neoplasms
Ultrasensitive and Reversible Nanoplatform of Urinary Exosomes for Prostate Cancer Diagnosis.
Prostatic Neoplasms
Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood.
Prostatic Neoplasms
Ultrasmall Renally Clearable Silica Nanoparticles Target Prostate Cancer.
Prostatic Neoplasms
Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer.
Prostatic Neoplasms
Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
Prostatic Neoplasms
Unusual Case of Diffuse Penile Metastasis of Prostate Cancer on 68Ga PSMA PET/CT Imaging and 177Lu PSMA Posttherapy Scintigraphy.
Prostatic Neoplasms
Upcoming Role of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Detecting Occult Metastases in Prostate Cancer.
Prostatic Neoplasms
Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.
Prostatic Neoplasms
Update on fused capromab pendetide imaging of prostate cancer.
Prostatic Neoplasms
Updates of prostate cancer staging: Prostate-specific membrane antigen.
Prostatic Neoplasms
Updates on the diagnosis and treatment of prostate cancer.
Prostatic Neoplasms
UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol).
Prostatic Neoplasms
Uptake of (18)F-DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies.
Prostatic Neoplasms
Uptake of an Acrochordon Incidentally Detected on 68Ga Prostate-Specific Membrane Antigen PET/CT.
Prostatic Neoplasms
Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in avascular necrosis of the femoral head.
Prostatic Neoplasms
Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi.
Prostatic Neoplasms
Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review.
Prostatic Neoplasms
Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients.
Prostatic Neoplasms
Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Prostatic Neoplasms
Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer.
Prostatic Neoplasms
Utility of (68) Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma.
Prostatic Neoplasms
Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
Prostatic Neoplasms
Utility of Ga68 prostate-specific membrane antigen positron-emission tomography for pre-operative staging of high-risk prostate cancer in a prospective cohort.
Prostatic Neoplasms
Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging.
Prostatic Neoplasms
Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Prostatic Neoplasms
Validation of a [Al
Prostatic Neoplasms
Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT.
Prostatic Neoplasms
Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer.
Prostatic Neoplasms
Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted 18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern.
Prostatic Neoplasms
Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
Prostatic Neoplasms
Virus electrodes for universal biodetection.
Prostatic Neoplasms
Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
Prostatic Neoplasms
Visualizing Human Prostate Cancer Cells in Mouse Skeleton Using Bioconjugated Near-infrared Fluorescent Quantum Dots.
Prostatic Neoplasms
Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer.
Prostatic Neoplasms
We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate Cancer.
Prostatic Neoplasms
Well-Differentiated Thyroid Cancer Neovasculature Expresses Prostate-Specific Membrane Antigen-a Possible Novel Therapeutic Target.
Prostatic Neoplasms
Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients.
Prostatic Neoplasms
What to Trust, PSA or [68Ga]Ga-PSMA-11: Learn from Experience.
Prostatic Neoplasms
What's in a Label? Radioimmunotherapy for Metastatic Prostate Cancer.
Prostatic Neoplasms
When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities.
Prostatic Neoplasms
Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer.
Prostatic Neoplasms
[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery.
Prostatic Neoplasms
[(18)F]-DCFPyL Positron Emission Tomography/Magnetic Resonance Imaging for Localization of Dominant Intraprostatic Foci: First Experience.
Prostatic Neoplasms
[(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
Prostatic Neoplasms
[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].
Prostatic Neoplasms
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Prostatic Neoplasms
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Prostatic Neoplasms
[18F]-JK-PSMA-7 and [18F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice.
Prostatic Neoplasms
[68 Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma.
Prostatic Neoplasms
[68Ga]Ga-iPSMA-Lys3-Bombesin: Biokinetics, dosimetry and first patient PET/CT imaging.
Prostatic Neoplasms
[68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence.
Prostatic Neoplasms
[68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.
Prostatic Neoplasms
[68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?
Prostatic Neoplasms
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer.
Prostatic Neoplasms
[68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer.
Prostatic Neoplasms
[99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center.
Prostatic Neoplasms
[Advances in prostate-specific membrane antigen targeted therapies for prostate cancer]
Prostatic Neoplasms
[Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer].
Prostatic Neoplasms
[Consensus of Chinese experts on the application of molecular imaging targeting prostate specific membrane antigen in prostate cancer patients].
Prostatic Neoplasms
[Detection of PSA mRNA from the peripheral blood and pelvic lymph nodes in patients with prostatic cancer by means of reverse transcription-polymerase chain reaction (RT-PCR)]
Prostatic Neoplasms
[Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Prostatic Neoplasms
[Ga-68-PSMA PET/CT for prostate cancer].
Prostatic Neoplasms
[Hybrid imaging in prostate cancer : Status quo and future applications].
Prostatic Neoplasms
[Initial experiences with 99mTc-PSMA-SPECT/CT in patients with prostate cancer].
Prostatic Neoplasms
[Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].
Prostatic Neoplasms
[Modern radiation therapy planning and image-guided radiotherapy using the example of prostate cancer].
Prostatic Neoplasms
[Molecular multimodal hybrid imaging in prostate and bladder cancer].
Prostatic Neoplasms
[PET-CT and PET-MRI of the prostate : From (18)F-FDG to (68)Ga-PSMA].
Prostatic Neoplasms
[Positron emission tomography with computed tomography/magnetic resonance imaging for primary staging of prostate cancer].
Prostatic Neoplasms
[Positron-emission tomography in urooncology].
Prostatic Neoplasms
[Prostate-specific membrane antigen and its role in diagnosis of prostate cancer]
Prostatic Neoplasms
[Prostate-specific membrane antigen. A new sensitive molecular indicator in metastasizing prostatic cancer]
Prostatic Neoplasms
[PSMA-based theranostics for prostate cancer : From imaging to treatment].
Prostatic Neoplasms
[PSMA-radioguided surgery in localised recurrent prostate cancer].
Prostatic Neoplasms
[PSMA-targeted radioligand therapy in prostate cancer].
Prostatic Neoplasms
[Radionuclide therapy and diagnostics in urology].
Prostatic Neoplasms
[Recent progress of positron radionuclide labeled small molecule inhibitors of prostate specific membrane antigen for PET/CT imaging of prostate cancer].
Prostatic Neoplasms
[Related biomarkers in the diagnosis of prostate cancer].
Prostatic Neoplasms
[Salvage lymph node dissection for nodal recurrent prostate cancer].
Prostatic Neoplasms
[Significance of current bio- and molecular-markers in urological cancers]
Prostatic Neoplasms
[Significance of prostate-specific membrane antigen (PSMA). A neurocarboxypeptidase and membrane folate hydrolase]
Prostatic Neoplasms
[Significance of PSMA imaging in prostate cancer].
Prostatic Neoplasms
[The role of PSMA PET-CT in patients with metastatic prostate cancer].
Prostatic Neoplasms
[THE ROLE OF PSMA PET/CT IN IMAGING PROSTATE CANCER].
Prostatic Neoplasms
[Transcriptional activities of tumor-specific survivin promoter and PSMA promoter and enhancer in human prostate cancer: evaluation and comparison].
Prostatic Neoplasms
[Updated application of prostate-specific membrane antigen to the diagnosis and treatment of prostate cancer]
Prostatic Neoplasms
¹?F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
Pulmonary Disease, Chronic Obstructive
Genetic analysis of 56 polymorphisms in 17 genes involved in methionine metabolism in patients with abdominal aortic aneurysm.
Ranula
Recalcitrant plunging ranulas: a new approach to salivary tissue localization using prostate-specific membrane antigen positron emission tomography.
Sarcoidosis
Prostate-Specific Membrane Antigen PET/CT in Splenic Sarcoidosis.
Sarcoidosis
Prostate-Specific Membrane Antigen PET/CT: Uptake in Lymph Nodes With Active Sarcoidosis.
Sarcoma
Incidental Detection of a Radiation-Induced Soft-Tissue Sarcoma on 68Ga-PSMA PET/CT in a Patient Previously Treated for Prostate Cancer.
Seizures
Kindling increases brain levels of NAAG and seizures reduce activity of a NAAG-hydrolyzing enzyme, NAALADase.
Seizures
NAALADase (GCP II) inhibition prevents cocaine-kindled seizures.
Seizures
Seizures decrease regional enzymatic hydrolysis of N-acetyl-aspartylglutamate in rat brain.
Sepsis
Core temperature correlates with expression of selected stress and immunomodulatory genes in febrile patients with sepsis and noninfectious SIRS.
Solitary Kidney
177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney.
Spinal Cord Injuries
Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats.
Spinal Dysraphism
Evaluation of genetic variants in the reduced folate carrier and in glutamate carboxypeptidase II for spina bifida risk.
Splenosis
Abdominal Splenosis Mimicking Peritoneal Metastasis in Prostate-Specific Membrane Antigen PET/CT, Confirmed With Selective Spleen SPECT/CT.
Sprue, Tropical
Jejunal brush-border folate hydrolase. A novel enzyme.
Stroke
Biochemical characterization of human glutamate carboxypeptidase III.
Stroke
Early-onset ischaemic stroke: analysis of 58 polymorphisms in 17 genes involved in methionine metabolism.
Stroke
Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration.
Stroke
Glutamate carboxypeptidase II (GCPII) genetic variants as determinants of hyperhomocysteinemia: implications in stroke susceptibility.
Stroke
Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.
Stroke
Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition.
Stroke
Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury.
Stroke
Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.
Stroke
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Stroke
Suppression of Glutamate Carboxypeptidase II Ameliorates Neuronal Apoptosis from Ischemic Brain Injury.
Testicular Neoplasms
PET imaging in urology: a rapidly growing successful collaboration.
Tetanus
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.
Tetanus
DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer.
Thymoma
Incidental Detection of Type B2 Thymoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT Imaging.
Thyroid Carcinoma, Anaplastic
Theranostics in Thyroid Cancer.
Thyroid Neoplasms
Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Thyroid Neoplasms
Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study.
Thyroid Neoplasms
Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
Thyroid Neoplasms
Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
Thyroid Neoplasms
Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing?
Thyroid Neoplasms
PSMA expression in differentiated thyroid cancer: association with radioiodine, 18FDG uptake, and patient outcome.
Thyroid Neoplasms
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome.
Thyroid Neoplasms
The frequency of thyroid incidental findings and risk of malignancy detected by 68Ga-labeled prostate-specific membrane antigen PET/CT in prostate cancer.
Thyroid Neoplasms
The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer.
Thyroid Neoplasms
The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid Cancer.
Thyroid Neoplasms
Theranostics in Thyroid Cancer.
Triple Negative Breast Neoplasms
Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.
Tuberculosis, Spinal
Spinal Tuberculosis Mimicking as Prostate Cancer Metastases in Ga-68 Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography.
Urinary Bladder Neoplasms
Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature.
Urinary Bladder Neoplasms
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Urinary Bladder Neoplasms
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Vascular Diseases
Influence of a glutamate carboxypeptidase II (GCPII) polymorphism (1561C-->T) on plasma homocysteine, folate and vitamin B(12) levels and its relationship to cardiovascular disease risk.
Whooping Cough
N-acetylaspartylglutamate and beta-NAAG protect against injury induced by NMDA and hypoxia in primary spinal cord cultures.
Xerostomia
Comparison of Prostate-Specific Membrane Antigen Expression Levels in Human Salivary Glands to Non-Human Primates and Rodents.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.